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Abstract 
The increase in life expectancy observed over the last century has led to the emergence of a new 
set of pathologies that constitutes a new threat for the world population. Among these pathologies, 
neurodegenerative diseases have gained an increased impact on society. Despite originating from 
different genetic, environmental and regulatory factors, many neurodegenerative disorders show 
similarities at sub-cellular and molecular levels. A characteristic common feature of ageing-
related diseases is the self‐assembly of misfolded proteins into neurotoxic oligomers and fibrils, 
which are resistant to degradation and lack the functionality of the native protein.  
 
Among these increasingly concerning diseases, Alzheimer’s disease (AD) affects over 80 
individuals every day. Substantial epidemiological evidence shows an increased risk for 
developing AD in people affected by diabetes, which is associated with increased 
hyperglycaemia. The molecular mechanisms underlying the link between diabetes and AD remain 
elusive. For this reason, when approaching the study of AD, it is essential to consider the role that 
sugars play in disease development and, therefore, the role of post-translational modifications 
such as glycation. Contrary to glycosylation, glycation is an enzyme-free reaction that leads to 
attachment of a carbohydrate molecule to the protein and the formation of advanced glycation 
end-products (AGEs). Glycation is one of the pathological processes involved in diabetes and is 
thought to influence the structure of the islet amyloid polypeptide (IAPP), which plays a role in 
glycaemic regulation. Misfolded IAPP aggregates into toxic amyloid-like structures, very similar 
to the Abeta peptide (variants 1-40 and 1-42) deposits, often also heavily glycated, observed in 
AD patients. 
 
The aim of this thesis is to unravel the effects of glycation on the structure and aggregation of the 
peptides IAPP and two of the most common variants of Abeta by means of an integrative structural 
approach. 
 
Several biophysical techniques were employed to gain insights into the structural effects of 
glycation on the aggregation process of the IAPP and Abeta peptides. The occurrence and location 
of the glycation reaction was elucidated by mass spectrometry. The secondary structure variations 
upon glycation were observed by circular dichroism and nuclear magnetic resonance. 
Spectrofluorometric assays were employed to follow protein aggregation and glycation 
concomitantly. Finally, the morphological effects of glycation on amyloid fibrils were evaluated 
by high-resolution structural atomic force microscopy (AFM) studies.  
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Introduction  
1.1 Protein misfolding and aggregation 
Neurodegenerative diseases are an increasing health concern for which there are no treatments for 
the underlying pathologies. Many, but by no means all, of these diseases, despite having a 
multitude of different symptoms, are associated with the misfolding of normally soluble, 
functional peptides and proteins, and their subsequent conversion into intractable aggregates, of 
which the archetypal examples are amyloid fibrils (Table 1) (1). To understand the impact of 
amyloid diseases on our society, it has been estimated that every 67 seconds someone in the USA 
develops Alzheimer’s disease, while only 45% of these people have been told of this diagnosis. 
In the UK the cost of Alzheimer’s and dementia already exceeded 30 billion pounds, while the 
global cost of Alzheimer’s and dementia is estimated to be around 480 billion pounds. 
 
Table 1. Some human diseases associated with protein misfolding and amyloid aggregation. Modified 
from (2). 
Disease Aggregating protein or peptide 
Number of 
residues (a) 
Native structure of 
protein or peptide (b) 
Neurogenerative disease 
Alzheimer’s disease (c) Amyloid beta peptide  37-43 IDP (e) 
Spongiform encephalopathies 
(c,e) 
Prion protein or fragments thereof 230 IDP, alpha-helix 
Parkinson’s disease (c) α-Synuclein  140 IDP 
Amyotrophic lateral sclerosis (c) Superoxide dismutase 1  153 Beta-sheet, Ig-like 
Huntington’s disease (d) Huntingtin with polyQ expansion Variable Mostly IDP 
Non-neuropathic systemic amyloidosis 
Amyloid Light chain 
amyloidosis (c) 
Immunoglobulin light chains or 
fragments 
∼90  Beta-sheet, Ig-like 
Amyloid A amyloidosis (c) Fragments of serum amyloid A protein 76–104  Alpha-helix and 
unknown fold  
Senile systemic amyloidosis (c) Wild-type transthyretin  127 Beta-sheet,  
Hemodialysis-related 
amyloidosis (c) 
beta2-microglobulin  99 Beta-sheet, Ig-like 
Lysozyme amyloidosis (d) Lysozyme mutants 130 Alpha-helical, beta-
sheet 
Non-neuropathic localised amyloidosis 
Injection-localised amyloidosis 
(c)  
Insulin 21 and 30 Alpha-helical, insulin 
like  
Type II diabetes (c) Islet amyloid polypeptide  37 IDP 
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a Data refer to the number of residues of the processed polypeptide chains that deposit into aggregates, not of the 
precursor protein 
b According to structural classification of proteins (SCOP), these are the structural class and fold of the native states 
of the processed peptides or proteins that deposit into aggregates prior to aggregation. 
c Predominantly sporadic, although in some cases hereditary forms associated with specific mutations are well 
documented. 
d Predominantly hereditary, although in some cases sporadic forms are documented. 
e Intrinsically disordered protein or peptide. 
 
Amyloid fibrils are thread-like structures, the formation of which is associated both with a loss of 
function of the involved proteins and with the generation of often toxic intermediates (2,3). 
 
Commonly, the formation of amyloid fibrils follows the misfolding, the incorrect folding of the 
protein. If a molecule of the protein cannot form the correct intramolecular bonds required to fold 
correctly, it can interact and combine with other molecules to form aggregates. Therefore, protein 
misfolding and aggregation is the phenomenon by which a natively folded protein undergoes an 
aberrant conformational transition with subsequent formation of energetically stable, high 
molecular weight amyloid fibrils (Fig. 1 A). Aggregation can be triggered by post-translational 
modification (PTM) such as protein hyperphosphorylation, by mutations that cause the protein 
instability or by events that increase a specific protein concentration in the cell (e.g. lack/defect 
of clearance, chaperone imbalance, etc.). 
 
At the molecular level, amyloids are insoluble protein aggregates, characterised by a cross-beta 
quaternary structure (4). The reaction mechanism is not usually a simple transition from monomer 
to fibril. Most of the time, the transition between monomer and fibril has an intermediate step 
characterised by soluble prefibrillar oligomers that can vary in size, structure, stability and toxicity 
(1). An aggregated state represents a state of minimum free energy and is the theoretically most 
stable state for the majority of proteins (5). The aggregated conformation is energetically 
favourable, due to the minimum of free energy that is reached; however, it is blocked by a high-
energy barrier (Fig. 1 B). The beta sheet structures allow the formation of a large number of 
intermolecular hydrogen bonds, which are energetically very favourable (Fig. 1 C). Thus, the 
main driving force for the formation of amyloid fibrils is their high thermodynamic stability. 
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Figure 1. A protein can exist in various different states. A. After synthesis, unfolded proteins can follow 
different pathways. The initiating event in aggregation may be covalent modification of the disease protein, 
facilitating conversion of the protein to an abnormal conformation. Oligomeric (globular) intermediates 
may form, and then protofibrillar structures are assembled. Amyloid fibres can then form, possibly through 
association of protofibrillar intermediates, resulting in aggregates or inclusions. The intermediate species 
are hypothesised to be more toxic than either the precursor protein. Modified from (1). B. The relative 
thermodynamic stability of a protein’s native and amyloid states is regulated by the free energy difference, 
ΔG, of the two forms. Free energy of the amyloid state depends on the protein concentration, whereas the 
free energy of the native state is usually independent of it. Although, at certain concentration, the amyloid 
state and the native state have the same stability. Indeed, at concentrations over that critical one, a protein 
is more stable in the amyloid state than in its native state, but the native state can still exist briefly if there 
are high free-energy barriers that prevent the transition into the amyloid state. Modified from (1). C. Model 
of parallel beta-strand arrangement in amyloid fibrils. Adapted from (6), intermolecular H-bonds, loop 
between beta sheets and measurements in Å were added.  
 
Proteins characterised by complex or unstable conformation sometimes have difficulty achieving 
their native state. In these cases, the cell has several defence systems to help them to find their 
native functional conformation. For example, clearance mechanism and molecular chaperone 
should prevent aberrant protein aggregation. Disfunction of these cellular processes for control of 
protein homoeostasis can be trigger for protein misfolding diseases (7).  
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Once the aggregation process has taken place, the aggregated proteins are resistant to degradation 
and lack functionality. In addition, intermediate and end products of the aggregation process are 
acknowledged to be toxic to cells. Moreover, increasing evidence suggests that prefibril oligomer 
intermediates may be even more toxic than mature amyloid fibres (8). Protein misfolding, 
therefore, leads to depletion of cellular function, cell death, and reduction of functional tissue 
volume (3). 
 
Protein aggregation diseases are not exclusively related to the central nervous system; they can 
also appear in peripheral tissues. In general, the genes and protein products involved in these kinds 
of diseases are called amyloidogenic. Such diseases include type 2 diabetes (T2D), inherited 
cataracts, some forms of atherosclerosis, haemodialysis-related disorders, and short-chain 
amyloidosis, among many others. All these diseases have in common the expression of a protein 
outside its normal context, leading to an irreversible change into a sticky conformation rich in 
beta sheets that makes the protein molecules interact with each other. 
 
In summary, the propensity of a protein to undergo misfolding processes is determined by its 
thermodynamic stability, the free energy barriers associated with the transition, the rates of 
synthesis and degradation, the interaction with chaperones and the occurrence of PTM. Among 
these, glycation, an ageing-correlated PTM, is becoming increasingly implicated in the 
pathogenesis of misfolding diseases and it will be the further subject of investigation of this 
project. 
 
1.2 Amyloid fibrils 
A wide range of biophysical techniques have been employed to characterise the structure of 
amyloid fibrils formed from different types of proteins. Among these approaches, the most used 
have been X-ray fibre diffraction, X-ray crystallography of crystallised fragments, solid-state 
nuclear magnetic resonance (ssNMR), electron paramagnetic resonance (EPR), atomic force 
microscopy (AFM), electron-microscopy (EM), and recently also cryo-electron microscopy 
(cryo-EM) (4,9-14). 
 
On the microscopic scale, amyloid fibres are typically manifested in the form of thread like fibrils, 
characterised by 5 to 15 nm in diameter and with a length ranging up to the μm scale. Some fibrils 
also display a regular twist around their long axis. The fibrils are characterised by a cross-beta 
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structure firstly identified in 2004 by means of X-ray fibre diffraction (15). These beta strands are 
characterised by a specific pattern that is made up of single beta-strands that run perpendicular to 
the long fibril axis (4). These results were lately corroborated by means of Fourier transform 
infrared spectroscopy, solid-state nuclear magnetic resonance (ssNMR), and further X-ray 
crystallography (3,16,17). Another approach to follow the formation of amyloid fibrils is to use 
dyes that intercalate into the beta structures such as thioflavin-T (ThT), Congo red, or their 
derivatives (18,19). 
 
The beta-strands found in the fibrils are stacked on top of each other with an inter-strand distance 
of 4.8 Å as shown by the first reflection in the X-ray fibre diffraction pattern. Mostly, two or more 
beta-strands are found per layer of the fibril and the distance between these strands ranges from 6 
Å to 10 Å and this distance is recorded as a second reflection in the X-ray diffraction pattern (4). 
The beta-strands when stacked, are connected by inter-molecular hydrogen bonds that provide a 
surprising strength and stability to the amyloid fibrils (Fig. 1 C). In this pattern the consecutive 
beta-strands alternate directions so that the N-terminus of one strand is adjacent to the C-terminus 
of the next one. This distribution allows the inter-strand hydrogen bonds between carbonyls and 
amines to be planar, which is their preferred orientation. Furthermore, this arrangement produces 
the strongest inter-strand stability, further enhanced by the presence of multiple closely interacting 
sheets. 
 
Side chains face either the inside of the fibril core to build an interface, also called steric-zipper, 
or they stick out and are in contact with the surrounding environment (9). A model showing a 
parallel arrangement of beta-strands within a fibril is shown in figure 1 C.  
 
1.3 Formation of amyloid fibrils 
 
Most of the amyloid fibrils are characterised by a repetitive and highly ordered structure 
undergoing a specific process of fibril growth. The aggregation process is promoted by conditions 
that destabilise the native fold of the protein, such as high temperature, high pressure, low pH, 
organic solvents, natural or post-translational mutations (20-22).  
 
Their aggregation process is characterised by at minimum three microscopic steps: primary 
nucleation of monomers only, secondary nucleation of monomers on fibril surface, and elongation 
of fibrils by monomer addition.  
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According to the classical nucleation process, monomer-dependent secondary nucleation is 
defined as a process whereby nucleus formation from monomers is catalysed by aggregates 
composed of the same type of monomeric piece (Fig. 2). In this manner, the monomers form a 
nucleus on the surface of an already existing aggregate: secondary nucleation occurs in the 
presence of a parent seed aggregate of the same kind of monomers. In most cases, a nucleus is 
formed on the surface of an already existing aggregate, thus elongation process proceeds 
promptly. During elongation, monomers attach themselves to one end of the protofibrils.  
 
It is crucial to identify whether or not the monomer concentration affects the process. If it does, a 
high concentration dependence of the lag time is possible, otherwise only a weak dependence can 
emerge because a change in the monomer concentration has no direct effect on the nucleation 
pathway (23). 
 
Reason behind the occurrence of either primary or secondary nucleation is still under 
investigation. However, it is well known that certain proteins tend to preferentially follow one or 
the other mechanism. For example, monomer-dependant secondary nucleation has been inferred 
for several proteins including Abeta (23-26), IAPP (27), insulin (28), alpha-synuclein (29,30), and 
carbonic anhydrase (31).  
 
Figure 2. Mechanisms of fibrils formation. Primary nucleation involves monomers of one substance in 
solution. Elongation occurs by monomer addition to the ends of fibril, whereas secondary nucleation 
involves monomers of one substance on the surface of an already existing aggregate of the same substance. 
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1.4 The kinetics of amyloid fibrils formation 
The investigation of how different experimental conditions can influence the speed of protein 
aggregation is the focus of kinetics studies. To do so, it is crucial to follow the process leading to 
the formation of amyloid fibrils. One of the most common techniques takes advantage of the 
characteristic tinctorial property of amyloid structures, namely the ability to bind specific dyes 
such as Thioflavin T (ThT). Since the first description in 1959, ThT has become one of the most 
widely used fluorescent dyes for the staining of amyloid fibrils both in vivo and in vitro (32). 
When ThT binds to beta sheet-rich structures, a distinctive feature of amyloid aggregates, its 
fluorescence gets enhanced, leading to a characteristic red shift of its emission spectrum (6). 
 
Generally, when aggregation prone proteins are incubated in vitro with the ThT dye, the kinetic 
pattern of the spontaneous formation of amyloid fibrils, recorded as the variation in fluorescence, 
during the time, is shown as a sigmoidal curve. The curve is typically characterised by three main 
components: the lag phase, the growth phase, and the plateau phase (Fig. 3). 
 
The nucleation step, which happens in the lag phase, is characterised by monomers that undergo 
conformational changes and associate with each other. These monomers generate an oligomeric 
nucleus, characterised by the presence of beta structures. The transition to elongation depends on 
the amount of accumulated oligomeric nuclei, which act as seeds for protofibril formation. During 
the elongation phase, the nuclei rapidly grow by further association of monomers and form larger 
fibrils until saturation.  
 
As mentioned, the nucleation phase is thermodynamically unfavourable and occurs gradually, 
whereas the elongation phase is a much more favourable process and proceeds quickly. The 
limiting step in the process is the formation of nuclei/seeds to promote aggregation. Thus, amyloid 
formation can be substantially accelerated by the addition of preformed seeds (nuclei). The 
addition of seeds lowers the lag time and induces faster aggregate formation.  
 
The presence of seeds is not the only factor that affects the aggregation kinetics. Post-translational 
modifications, which can strongly influence the proteins subcellular localisation, activity, protein-
protein interaction, and their stability also plays a crucial role in protein aggregation (33). Post-
translational modifications are modification of proteins, occurring after protein biosynthesis, such 
as phosphorylation, arginine methylation, acetylation. Most of them involve an enzymatic 
reaction and produce a covalent bond. However, post-translational modifications can naturally 
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occur without the help of an enzyme. Among these, glycation has come to the light as a possible 
factor affecting the aggregation pathway and, therefore, it will be the subject of this project. 
 
 
Figure 3. Steps of amyloid fibrils formation. The kinetics of amyloid fibrils formation is represented by a 
sigmoidal curve, corresponding to consecutive steps of nucleation, elongation, and saturation. During 
nucleation, misfolded monomers associate with each other. They generate an oligomeric nucleus, 
characterised by the presence of beta structures. The transition to the elongation depends on the amount of 
accumulated oligomeric nuclei, which performs as seeds for protofibril formation. During saturation, 
mature fibrils are produced from protofibrils. Figure adapted from (34). 
 
1.5 Glycation 
Glycation is the result of a covalent bonding of a protein with a glycating agent, such a sugar 
molecule, without controlling action of an enzyme, as opposed to protein glycosylation that is 
characterised by an enzymatic reaction.  
 
Protein glycation occurs through the Maillard reaction of a protein amino group with glucose to 
yield a Schiff base, which undergoes a rearrangement to form a so called Amadori compound 
(Fig. 4 A) (34). Subsequently, this compound is subject to decomposition, fragmentation and 
condensation, to yield advanced glycation end-products (AGEs). Glucose, Schiff base and 
Amadori compound can also exhibit auto-oxidation reactions that are responsible for the 
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formation of oxygen free radicals and production of highly reactive carbonyl compounds. AGEs 
can affect protein structure and function in nearly every type of cell in the body, in particular, they 
are believed to play the causative role in the vascular complications of type-2 diabetes (T2D). 
Under certain pathological conditions, such as oxidative stress due to hyperglycaemia in diabetic 
patients, AGE formation can increase beyond normal levels. 
 
In biological systems, glycation can occur with the N-terminal of proteins and peptides and the 
side chain of amino acids such as lysine, arginine, cysteine and histidine (35). The reaction is not 
available to non-reducing sugars, such as sucrose, where the aldehyde or ketone groups have been 
converted to a glycosidic bond. In addition to glucose, glycation can be initiated by other 
carbonyl-containing compounds, such as methylglyoxal (MGO) and oxidized lipids (36). In 
particular, glucose is relatively unreactive compared to MGO, a short, open-chained dicarbonyl 
compound. MGO, a metabolite of glucose, primarily reacts with arginine or lysine residues and 
is estimated to be 20,000-50,000 times more reactive than glucose (Fig. 4 B) (37-39). Since it is 
such a powerful glycating agent, the accumulation of the cell-permeant MGO can be extremely 
harmful. The glycation reaction involves first the production of a reversible Schiff base which can 
slowly rearrange to give rise to the stable Amadori compound product (Fig. 4 A). Subsequently, 
these species can undergo further rearrangement and eventually various chemical reactions, 
resulting in the formation of advanced glycation end-products (AGEs), of which there are over 








Figure 4. A. Schematic presentation of the Maillard reaction. Reactive carbonyl groups of a reducing sugar 
react with neutrophilic free amino groups of proteins to form a reversible Schiff base. Through 
rearrangement a more stable Amadori product is formed. B.Fischer projections of the simplified glycolysis 
process, the metabolic pathway converting glucose into pyruvate. This pathway involves the intermediate 
metabolite fructose-1,6-bisphophate (fructose-1,6.bis-P) that can be converted into two trioses: 
glyceraldehyde-3-phospate (glyceraldehyde-3-P) and dihydroxyacetone-3-phospate (dihydroxyacetone-3-
P). MGO is formed from glyceraldehyde-3-P and dihydroxyacetone-3-P th 
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at accumulate when glyceraldehyde-3-phosphate dehydrogenase activity is inhibited by hydrogen peroxide 
(41,42). Modified from (43). 
 
1.6 Advanced glycation end-products  
In the last years, advanced glycation end products (AGEs) have received particular attention in 
the context of aging. AGEs can be obtained from the diet or can be formed endogenously. High-
heat and dry-cooking methods produce a very large amounts of AGEs in food, whereas raw food, 
boiled, or simmered tend to be lower in AGEs (44). Fatty foods such as butter or oil have the 
highest amounts of AGEs per gram, even prior to heating, followed by cooked meats (45,46). 
 
AGE endogenous formation is typically a slow process that occurs on long-lived extracellular 
proteins (40). However, MGO-modified peptides can rapidly generate AGEs. MGO-induced 
glycation of arginine residues forms argpyrimidine (ArgP) and hydroimidazolone, while the 
lysine-derived AGEs are Nε-carboxymethyl-lysine (CML) and Nε(1-carboxyethyl) lysine (CEL). 
(Fig. 5) (38,40,47-49). The methylglyoxal-derived hydroimidazolone is one of the most 
quantitatively and functionally important AGEs in physiological systems, as early indicator of 
atherosclerotic process in diabetes (50). Interestingly, increased levels of circulating CML was 
able to predict hospitalisation and it was independently associated with a higher risk of mortality 
in a large cohort of heart failure patients (51). 
 
High concentrations of AGEs may induce toxicity via aberrant cross-linking with proteins, 
binding to cell-surface receptor RAGE (receptor for AGEs) and production of oxygen free radicals 
(52). RAGE stimulation can inhibit and induce cytoprotective and cytotoxic signalling pathways, 
respectively, and is becoming increasingly implicated in the pathogenesis of misfolding diseases 
(53,54).  
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Figure 5. MGO-induced glycation reaction. Glycation involves MGO with primary or secondary amine 
groups on protein residues (N-terminus, Arg, Lys) producing advanced glycation end-products (AGEs) 
such as hydroimidazolone, the fluorescent argpyrimidine product (ArgP), carboxyethyl-lysine (CEL), 
carboxymethyl-lysine (CML) etc. 
 
1.7 AGEs and their association with neurodegenerative diseases and diabetes 
The formation of AGEs promotes the deposition of proteins leading to the abnormal accumulation 
of the modified proteins. Numerous proteins involved in neurodegenerative diseases such as 
Abeta, tau, alpha-synuclein, and prions are glycated, and the extent of glycation is correlated with 
the pathologies, suggesting that AGEs encourage the development of neurodegenerative diseases 
(55,56). Southern et al (57) analysed brain sections from 25 AD patients with varying degrees of 
cognitive dysfunction and cerebrovascular pathologies and found that impaired cognition was 
correlated with higher content of AGEs such as carboxymethyl-lysine in the vasculature and the 
cortical neurons. The amount of AGEs measured was also proportional to the severity of diabetes. 
Moreover, Valente et al (58) demonstrated that the brains of people affected by both AD and 
diabetes have higher amounts of AGEs’ deposits and upregulation of RAGE compared to non-
diabetic patients affected just by AD. Patients with both diseases had a greater presence of dense 
plaques. The large presence of AGEs in the neurofibrillary pathology of AD heavily supports that 
AGEs have a crucial role in the neuropathogenesis of AD (47,56). Due to their implication in the 
progression of neurodegenerative and diabetic diseases, AGEs represent a hotspot and could give 
more information about the aetiology of both diseases. 
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1.8 Glycation and protein misfolding  
Glycation is well known to play a significant role in modifying protein structure and functions, as 
reported for a broad range of folded proteins (59). Moreover, it is expected to have a drastic effect 
on the biological function and biophysical properties of intrinsically unfolded polypeptides (59), 
although much less is currently known on this topic. Two of such examples are the aggregation-
prone peptides amyloid-beta peptide (Abeta) and islet amyloid polypeptide (IAPP). IAPP is a 
peptide associated with glycation in T2D patients (60). It is generally accepted that aggregation 
of IAPP in T2D causes loss of insulin-producing pancreatic beta-cells (61). The associated 
hyperglycaemia increases the occurrence of glycation (62): Ma et al. (60) showed that the 
extracted IAPP displayed glycation by in situ investigations in human pancreatic deposits. 
Moreover, Abeta, associated with AD, is also subject to glycation and amyloid fibrils have been 
found to be glycated in patients affected by this disease (63). This evidence again suggests a 
central role of glycation in both diabetic complications and neurodegenerative processes such as 
AD. For this reason, it is crucial to investigate if glycation affects molecular events responsible 
for protein aggregation and self-assembly of proteins involved in AD and in T2D, such as Abeta 
and IAPP respectively.  
 
1.9 Abeta 
One of the main hallmarks of AD is the deposition of amyloid plaques and neurofibrillar tangles 
in the brain (64-67). The major component of the amyloid plaques is a peptide called amyloid 
beta peptide (Aβ or Abeta), which was first identified by Glenner and Wong in 1984 (68,69). On 
the other hand, neurofibrillary tangles mainly consist of aggregated tau protein, a protein involved 
in the stabilisation of microtubules (70). Abeta denotes peptides of 36–43 amino acids, and the 
two most common forms are Abeta40 and Abeta42 that have a molecular mass of about 4.3 and 
4.5 kDa, respectively. Abeta is a product generated through a sequential cleavage of the amyloid 
precursor protein (APP). APP is a glycoprotein, expressed in several tissues, especially in the 
synapses of neurons and its role has been described as crucial in AD pathogenesis (65,67). It is a 
membrane protein with one transmembrane helix where the C-terminus is intracellular and the 
Abeta domain is localised both in the membrane and extracellularly. APP covers a regulatory role 
in synaptic formation and repair (71), anterograde neuronal transport (72) and iron export (73). 
This membrane protein is produced as several different isoforms, ranging in size from 695 to 770 
amino acids. The sequential proteolytic process of APP can follow a non-amyloidogenic and an 
amyloidogenic pathway, through the enzymes a, b and g-secretase (Fig. 6A) (64,65,67). 
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Figure 6. Amyloidogenic and non-amyloidogenic pathways of APP, the Abeta precursor protein. A. APP 
undergoes a sequential proteolytic cleavage by α- and γ-secretase via a non-amyloidogenic pathway. The 
α-secretase produces sAPPα extracellularly and C83 embedded in the membrane. C83 can be further 
cleaved by γ-secretase producing P3 and AICD, which are not toxic. The amyloidogenic pathway, which 
generates Abeta, is initiated by β-secretase cleavage producing the secreted sAPPβ extracellularly and the 
C99 embedded in the membrane. C99 can be subsequentially cleaved by γ-secretase, producing Abeta 
extracellularly and AICD intracellularly. Adapted from (69). B. Schematic structure of APP, C99 and 
Abeta. C. Primary structure of Abeta40 and Abeta42. 
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In the non-amyloidogenic pathway, APP undergoes serial proteolytic cleavages by α- and γ-
secretase, precluding Abeta generation. This pathway is initiated by α-secretase, that acts on the 
extracellular membrane side and releases the extracellular fragments, called s-APPα  The resulting 
C-terminal fragment C83 (APP688-770), which is still embedded in the membrane, can be further 
cleaved by the γ-secretase, releasing a non-amyloidogenic fragment P3 and the APP intracellular 
C-terminal domain (AICD) (Fig. 6 A, B).  
 
In contrast, the amyloidogenic pathway is mediated by the b and g-secretase, leading to 
extracellular release of amyloidogenic Abeta. B-secretase cleavage produces the secreted s-APPβ, 
and the C-terminal fragment, C99 (APP672-770). C99 can be cleaved by γ-secretase, producing 
extracellular Abeta and intracellular AICD (64,65,67). The cleavage by γ-secretase can occur on 
several sites between residues 38-42 (64). This process produces mainly Abeta(1-40) and 
Abeta(1-42) (from now on called Abeta40 and Abeta42) and their ratio is believed to play a crucial 
role in the rate of amyloid formation (64). Despite Abeta40 and Abeta42 differ for just two amino 
acids (isoleucine and alanine), they act differently: Abeta42 is more prevalent in amyloid plaques 
and it is the more fibrillogenic of the two (66,74). The sequences of Abeta40 and Abeta42 are 
shown in figure 6 C. 
 
1.9.1 Abeta secondary structure  
Abeta is an aggregation-prone peptide, that varies its structural state at different stages in the 
aggregation process. Abeta may adopt different secondary structures including random coil-like, 
beta-structured and alpha-helical states depending on the environmental conditions (75).  
 
Before the g-secretase cleavage, Abeta is part of the transmembrane domain of C99, which is 
characterised by two helical domains. A short extracellular N-helix (APP688- 694) is connected by 
an N-loop (APP695- 699) to the helical transmembrane domain (TMD or APP700-723) (76). The N-
helix is embedded in the membrane surface and will be part of cleaved Abeta peptides combined 
with the helical TMD (77) (Fig. 7). Thus, Abeta exhibits an alpha-helical structure in a membrane 
environment. This secondary structure was described firstly in 1994 using NMR spectroscopy on 
the fragment Abeta (1-28). Once Abeta was dissolved in solution and abandoned the membrane-
like environment, a transition from alpha-helix to beta-sheet conformation was described (78). 
The presence of alpha-helix structure was lately confirmed using the entire full-length peptide: in  
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the presence of sodium dodecyl sulphate (SDS) micelles, Abeta formed two alpha-helices 
involving residues Abeta15–24 and Abeta29–35 corresponding to the N-helix and the helical TMD 
belonging to the C99 fragment of APP (79,80) (Fig. 7). 
 
 
Figure 7. Schematic representation of C99 tertiary structure. C99 is the peptide resulting from the cleavage 
of APP by γ-secretase. In C99 two helical domains are identified: a short extracellular N-helix (APP688- 
694) and a helical transmembrane domain (TMD or APP700-723). They are connected by an N-loop 
(APP695- 699) (71). When C99 undergoes γ-secretase cleavage, Abeta is released, whose number 
sequence is in grey above. 
  
However, Abeta is classified as an intrinsically disordered protein (IDP) i.e. under physiological 
conditions, the peptide lacks a stable tertiary structure (81,82). For this reason, it cannot be 
crystallised by common methods, but NMR, CD and molecular dynamics are suitable techniques 
to carry out structural investigation on its secondary structure. Thus, NMR and CD spectroscopy 
were used to elucidate how Abeta monomers are predominantly unstructured (83,84). Despite the 
typical IDP properties, NMR studies showed that Abeta could exhibit alpha-helix or beta-sheet 
conformation dependant on the environment conditions.  
 
In 1998 and 2000, two studies were carried out incubating Abeta peptide in the presence of SDS 
micelles to mimic the membrane-like environment and in hydrophilic conditions, respectively. In 
the presence of SDS micelles, Abeta40 exhibited alpha-helix conformation at the C-terminus 
(Abeta15-36) with a kink or hinge at around amino acids 25-27. While the N-terminus of the peptide 
(Abeta1-14), whose residues are mainly polar and likely solvated by water, was unstructured. The 
deprotonation of two acidic residues in the helix promoted a helix-to-coil conformational 
transition that preceded the aggregation of Abeta40 (85). Whereas, in aqueous environment, Abeta 
collapsed into a compact series of loops and strands and did not exhibit any alpha-helical or beta-
sheet structure. Almost one fourth of the surface was continuously hydrophobic and the compact 
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random coil structure would lead to a general conformational rearrangement with the formation 
of an intermolecular beta-sheet secondary structure generated by fibrillisation (86). 
 
The presence of helical structure in a lipidic environment was further confirmed in 2002 and 2004 
by means of NMR spectroscopy. Two distinct helical regions in Abeta core were described, by 
analysing 3D NMR structures of the Abeta peptide (8-25) and Abeta peptide (28-38). In addition, 
the Abeta peptide (25-35), which is a very toxic derivative, behaved as a typical transmembrane 
helix in a membrane-like environment, leading to fibrillar aggregates. These results suggested a 
direct link between structure and neurotoxicity (87,88). 
 
In the late 2000, different conformational states of Abeta40 and Abeta42 were described by means 
of molecular dynamics and NMR spectroscopic studies. NMR-guided simulations showed that 
the C-terminus of Abeta42 was more structured than previously assumed and that residues 31-34 
and 38-41 formed a protein structural motif called beta-hairpin. This particular structure consists 
of two strands that were adjacent in the peptide’s primary structure where the N-terminus of one 
sheet lied on the C-terminus of the other. In this study, the beta-hairpin reduced the C-terminal 
flexibility, a factor that could be responsible for the more fibrillogenic behaviour of Abeta42 than 
Abeta40 (89). Moreover, molecular dynamics studies suggested that Abeta40 and Abeta42 were 
characterised by the rapid transition between alpha-helix and beta-sheet conformers (89). 
However, in 2011, a NMR study indicated that Abeta40 displayed a significant secondary and 
tertiary structure in aqueous environment (90). This outcome was the foundation for further 
studies showing that the hydrophobic C-terminal of Abeta played a crucial role in the transition 
from alpha-helical to beta-sheet structure (91). 
 
1.9.2 Abeta secondary structure organisation 
Abeta undergoes an aggregation process leading to the formation of long and mature amyloid 
fibrils characterised by a high content of secondary beta-sheet structures. Using X-ray diffraction, 
Abeta fibrils show a highly regular cross-beta diffraction pattern, characterised by an intersheet 
distance of 4.8 and 10 Å along and perpendicular to the fibril axis, respectively, which is 
characteristic of amyloid aggregates. Numerous structural biology techniques have been 
employed to investigate the structure of amyloid fibrils (92-102). 
 
Scanning transmission electron microscope (STEM), EM and ssNMR, suggested that the 
supramolecular structures of fibrils derived from Abeta40, Abeta42 and from the peptide 
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Abeta(10-35) were organised as beta-sheets (92,93). Several ssNMR methods revealed that 
amyloid fibril cross-beta structures exist in two patterns: parallel and antiparallel depending on 
the direction of the peptide strands (Fig. 8) (94-96). Parallel structures are more stable due to the 
fact that they have more ordered residues, longer beta strand segments and more ordered packing 
of hydrophobic side chains (97). Antiparallel fibrils are thermodynamically metastable i.e they 
are in an equilibrium state, which does not correspond to an absolute minimum of energy. 
When the beta strands are in parallel, they can be in-register with aligned residues or out-of-
register with non-aligned residues (Fig. 8).  
 
 
Figure 8. Hydrogen bond pattern in the parallel and anti-parallel arrangements of the beta strands in beta-
sheets. Beta strands can be in the parallel and anti-parallel arrangements and they are characterised by a 
specific hydrogen bond pattern. Beta sheets are parallel if the polypeptide strands run in the same direction, 
N-terminus to C-terminus, indicated by the blue arrows.  The N-terminus of one beta strand is opposite the 
N-terminus of the other beta strand. The hydrogen bonds are not perpendicular to the individual strands. 
Anti-parallel beta-sheet arrangement occurs when a polypeptide chain sharply reverses direction. This can 
occur in the presence of two consecutive proline residues, which create an angled kink in the polypeptide 
chain and bend it back upon itself. The hydrogen bonds pattern is perpendicular to the individual strands.  
 
Multiple quantum 13C NMR data indicated that beta strands were arranged in parallel, in particular 
in parallel an in-register, parallel organisation in Abeta peptide (94). In addition, the cross-beta 
structure pattern was confirmed on both Abeta40 and Abeta42 by means of various ssNMR 
studies (16,94-96,99,103) (Fig. 9). Among these studies, a parallel alignment of the beta-sheets  
was described in both Abeta variants (94-96) (Fig. 9 A). However, when Abeta was subject to a 
single substitution described by Iowa et al. (D23N-Abeta), which is associated with early onset 
familial AD, showed both parallel and anti-parallel patterns suggesting a correlation between beta-
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sheet alignment and certain AD onset (97,101) (Fig. 9 B). The anti-parallel alignment in Abeta 
resulting from the Iowa variant is thermodynamically less favourable compared to parallel 
arrangement (97). Nonetheless, the anti-parallel form appeared to be more common when Iowa-
mutant Abeta aggregates without additional seeding, pointing out the higher propensity for 
spontaneous nucleation of this mutated Abeta (97). 
 
It is remarkable that Abeta can exhibit both parallel and anti-parallel arrangements in different 
conditions. Tycko’s research group presented several works about this compelling subject. They 
compared Abeta fibrils formed from parallel and antiparallel beta sheets demonstrating that 
antiparallel sheets nucleated faster and were metastable with respect to parallel structure 
conversion. Both types of fibrils were demonstrated to be equally neurotoxic (97).  
  




Figure 9. Structural states of Abeta in fibrils showing a parallel or antiparallel pattern. A. Abeta42 fibrils 
contain two parallel beta sheets in residues 18–26 and 31–42 (protein data bank - PDB code 2BEG) (90). 
B. Abeta40 with the Iowa variant D23N exhibits an anti-parallel alignment (PDB code 2LNQ) (92). Red 
arrows indicate the repeating unit of protein for each beta sheet structure. 
 
1.10 IAPP 
The primary pathology in T2D is hyperglycaemia, i.e. high blood glucose, caused by a 
combination of insulin resistance and pancreatic beta-cell loss, leading to a lack of insulin  
 
production (104). One major accepted cause of pancreatic beta-cell death is the aggregation of 
IAPP, a small peptide hormone co-produced and co-secreted along with insulin from the 
endocrine beta-cells of the pancreas (105). IAPP is the primary constituent of amyloid deposits in 
the pancreatic islets. The extent of beta-cell loss is correlated with extracellular accumulation of 
IAPP aggregates and over 90% of T2D patients have pancreatic islet IAPP aggregates 
(104,106,107). 
 
IAPP, also called amylin, is derived from an 89 residue pre-pro-hormone. After cleavage of the 
signal sequence, it results in the 67-residue pro-form, which is processed in the Golgi and in the 
insulin beta-cell secretory granule to yield the mature hormone. The mature 37-residue peptide 
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requires further processing and post-translational modifications such as amidation of the C-
terminus and the formation of an intramolecular disulphide bridge between Cys2 and Cys7. 
 
Despite the cytotoxicity of the non-amidated variant, the lack of amide group on the C-terminus 
may initiate different aggregation processes by affecting the hydrophobic structures, 
conformations, and intra-sheet interactions of the peptides (108). It was extensively demonstrated 
that both features resulting from post-translational modifications, C-terminus amidation and 
disulphide bridge, are necessary for full biological activity (109,110). For this reason, obtaining 
the IAPP C-terminal amidation is extremely relevant, as suggested by Cottingham et al. who 
presented a suitable protocol to produce C-terminal amidated IAPP expressed as a fusion protein 
(111).  
 
At physiological pH, IAPP is slightly positively charged, thanks to residues Lys1, Arg11, and 
His18. Despite the charged residues, IAPP is also characterised by hydrophobic features because 




Figure 10. Primary structure of human IAPP. The sequence of mature human IAPP with oxidised 
intramolecular disulfide bridge and amidate C-terminus. 
 
As an intrinsically disordered peptide, IAPP does not adopt a compact globular structure in its 
physiological soluble form. This was demonstrated by means of solution NMR studying the 
interactions between amylin and membranes. Patil et al. elucidated IAPP behaviour in several 
environments such as water, ranging pH from 4.3 to 7.3 and using different SDS micelles 
concentrations (112,113) (Fig. 11 A). IAPP is stored in secretory granules at pH 5.5 (114), an 
environment that favours the protonated state of His18 and contributes to stabilise the soluble 
monomer, due to electrostatic repulsion (115). In addition, co-storing of IAPP and insulin in the 
granules stabilises the soluble form of IAPP. 
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IAPP is widely regarded as a natively unstructured protein (116,117), however, it is highly prone 
to aggregation and formation of insoluble cytotoxic amyloid aggregates and fibrils (61). In 
patients affected by T2D, IAPP undergoes conformational changes to form highly-ordered beta 
sheets organised into amyloid fibres. Amyloid plaques are formed by masses of fibrils, but 
growing evidence suggests that the toxic species may be prefibrillar intermediates (2,116). 
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Figure 11. IAPP structure. A. Structures of human IAPP. (left) Monomeric IAPP in 100mM SDS micelles, 
pH 4.3 (PDB: 2KB8), (middle) 200mM SDS micelles pH 7.3 (PDB: 2L86) and (right) water (PDB: 
5MGQ). Adapted from (109). B. Primary structure of human and rat IAPP. Residues belonging to the 
region considered the most amyloidogenic in human IAPP are in blue. Residues in red correspond to 
sequential differences in the primary sequences. C. Schematic diagram of the primary sequence of hIAPP. 
Blue circles indicate the cysteine amino acid C2-C7 disulphide bond. Orange circles indicate hydrophobic 
regions, with the aromatic residues (Phe15, Phe23 and Tyr37) in red. Bolt-circled represent some amino 
acids implicated in IAPP amyloidogenicity. Modified from (110).  
 
1.10.1 IAPP amyloidogenicity and its aggregation structure  
There is much interest in understanding the mechanism by which these proteins form fibrils and 
identifying intermediates in the aggregation pathway. However, obtaining structural information 
about intermediate species is difficult due to their transient nature. For this reason, slowing down 
the aggregation process could be a successful approach to understand the dynamics of aggregation 
and glycation of IAPP.  
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The variant frequently employed to study the self-assembly process of IAPP is the rat one (rIAPP), 
due to its lower tendency to aggregate. The sequence of rIAPP differs from the human IAPP 
particularly in the region of amino acids 25-29 (IAPP25-29) (Fig. 11 B), which is important for 
amyloid fibril formation. The main difference  in three proline residues at 25, 28, and 29 positions: 
human IAPP mutated to contain these three proline residues aggregates to a lesser extent (118). 
 
Proline imposes a restriction on backbone conformational freedom and is known to be a beta-
sheet breaker. The aggregation properties of segment 20-29 (IAPP20-29) have been subject of study 
as it was first believed to be the only segment of human IAPP responsible for amyloid formation. 
 
Studies probing the minimum number of residues required for amyloidogenicity of region IAPP20-
29 elucidated Phe23 as an important residue: fragment IAPP(24-27) lacked amyloidogenicity and 
cytotoxicity whereas fragment IAPP(23-27) aggregated at the fastest rate of all fragments and 
maintained cytotoxicity (119). However, other substitutions and/or chemical additions can inhibit 
or induce aggregation of the same fragment, and substitutions outside of the major amyloidogenic 
region can also influence aggregation propensity (Fig. 11 C) (120-124).  
 
Upon the unquestionable crucial role of region 20-29, subsequent investigations identified other 
segments as amyloidogenic in human IAPP. In particular, segments IAPP(8-20), IAPP(30-37) 
and also the N-terminus IAPP(1-8) are able to form fibrils (125-127). 
 
1.10.2 IAPP’s amyloid fibril structure models 
Different biophysical approaches were employed to elucidate the IAPP fibrils structure and the 
obtained insights were combined to build several structural models. Figure 12 shows the beta-
strand regions as defined in the studies mentioned on the right. 
  




Figure 12. Location of beta-strands in IAPP fibrils as found in different studies. The arrows show the beta-
strand regions. From the top, first represents the serpentine model, obtained from EM studies (128), the 
solid-state NMR model (122), the model based on crystallised segments (123), d) the EPR model with 
staggering about 3 fibril layers (124), and e) the model derived from 1H solvent protection (125). 
 
In 2004, X-ray and electron diffraction studies demonstrated the cross-beta diffraction pattern 
(15). The same year, electron paramagnetic resonance (EPR) was employed to describe an in-
register-parallel arrangement of beta-strands in the fibrils (128). These outcomes and prior 
evidence from electron microscopy (129) were combined in 2005 to generate a serpentine model 
(130). The authors proposed a beta-serpentine fold composed of three beta-strands, separated by 
two turns. In particular, segment IAPP22-27 was responsible of forming a beta-strand in this model. 
 
The most detailed structural models of IAPP fibrils come from solid-state NMR (ssNMR). A 
highly cited structural model based on a ssNMR study was published in 2007 (131). It 
corroborated the in-register-parallel arrangement by distance constraints gained from dipolar re-
coupling experiments and it shared the steric-zipper motif, where the side chains of the beta 
strands are firmly interdigitated, another common structural motif of amyloid fibrils (132).  
 
In addition, inter-strand side-chain contacts of residues from opposing beta-strands were 
illustrated. In this model, two beta-strands per monomer were described, located at positions 
IAPP8-17 and IAPP28-37 and separated by a non-constrained loop. A symmetric dimer model was 
proposed, with a C2 symmetry about the long fibril axis. The inner beta sheets were composed of 
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segments IAPP28-37 and the outer sheets of segments IAPP8-17. The N-terminus was not 
constrained in this model (131) (Fig. 13). 
 
 
Figure 13. Molecular structural models for the protofilament in IAPP fibrils. Proposed by Luca et al. (122). 
Left. Ribbon representation of one cross-beta molecular layer, with N-terminal and C-terminal beta-strand 
segments in red and in blue, respectively. The black arrow indicates the fibril axis. Right. Cross-sectional 
view of two IAPP molecules in the protofilament, characterised by a configuration, with approximate C2 
symmetry about the fibril axis. Modified from (131). 
 
In 2008, straight after the model proposed by ssNMR, X-ray crystallography yielded a similar 
model (133) which, however, differed in the details of the packing of side chains. In this study, 
segments 21NNFGAIL27 and 28SSTNVG33 were crystallised. The model also described two 
beta-strands per monomer located at positions IAPP8-17 and IAPP24-37, and also confirmed a 
symmetric dimer as subunit, with a C2 symmetry about the long fibril axis. The outer beta sheets 
were composed of segments IAPP24-37 (instead of IAPP28-37 as suggested by the ssNMR) which 
built the dry steric-zipper interface in between two symmetric monomers in one fibril layer (133).  
 
The fourth structural model, presented in 2012, was based on EPR studies and it was based on 
previous work from 2004 (13,128). This EPR-based model proposed two beta-strands at the 
following positions: IAPP12-19 and IAPP31-36. This model is the only one describing a stagger of 
the two strands about three peptide layers (Fig.14 A) (128).  In this study, the fibril was a left-
handed helix that contained IAPP monomers in a novel staggered conformation. The two beta-
strands of the monomer adopted out-of-plane positions and were staggered by about three peptide 
layers (∼15 Å). In figure 14 B the two strands separation is indicated with a red dashed line.  





Figure 14. A. IAPP monomer according to EPR model, viewed along the fibril axis (top) and viewed 
along an axis orthogonal to the fibril axis (bottom), showing the stagger of the two beta-strands of the 
IAPP peptide. B. A section of the structural model showing the stagger of the IAPP peptides shown as 
blue, green, and orange ribbons displayed with the axes of beta-strands perpendicular and orthogonal to 
the fibril. Image adapted from (128), the ∼15 Å distance between the three peptide layers and the red 
dotted lined indicating the strands stagger were added. 
 
The last model is based on an amide proton solvent protection study, a method to study a 
supramolecular complex of amyloid fibrils. (134). In this case, a different type of chemical 
exchange process was employed to have information about amide protons involved in a secondary 
structure and their stability. After lyophilising a D2O-dissolved protein, it is dissolved in DMSO, 
which has a double function: firstly, dissolving any amyloid structure in their monomeric forms, 
secondly, as an aprotic solvent, DMSO has no labile hydrogen atoms that potentially exchange 
with amide hydrogen of proteins (135). Consequently, a significant deceleration of the 
hydrogen/deuterium exchange reaction allows to monitor the exchange reaction in a larger 
window of time (134,136). 
Introduction 
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This model based on an amide proton solvent protection investigation shared partially similar 
beta-strand regions as the ssNMR model, in particular including His18 as the last residue in the 
first strand beta. His18 plays a central role, since its ionisation state is critical in determining the 
pH dependence of fibrillisation (137) and because replacement of His18 with positively charged 
arginine reduces amylin toxicity (138). In addition, with this method, residues Ile26 and Leu27 
were described as more protected, so more conformationally constrained. By showing a higher 
protection than the loop residues, therefore, Ile26 and Leu27 were included in the second beta-
strand in this method.  
 
In conclusion, the presence of two beta-strands per monomer is overall accepted throughout all 
models (128,131,133,134), except for the serpentine one, suggesting three beta-strands (130). The 
exact length and position of the strands differs in the models described (Fig. 12). The described 
dissimilarities could be explained by polymorphism, due to different sample preparation protocols 
(139,140). Regarding the controversial amyloidogenic sequence IAPP20-29, it is surprising that it 
is not a constant part of secondary structure, quite the opposite, it is mostly regarded as part of a 
random coil loop. 
 
2. Aim of this work 
My aims were to study the role of glycation, a post translational modification, PTM, consisting 
of the non-enzymatic addition of sugars to proteins, on the structure, aggregation pathway and 
toxicity of two peptides involved in T2D and AD: IAPP and Abeta, respectively. Therefore, my 
aim was to investigate the molecular mechanism leading to amylin and Abeta misfolding and 
subsequent aggregation and the role of glycation on these inexorable processes in proteinopathies. 
These diseases, also known as protein misfolding diseases, refer to a class of diseases in which 
specific proteins fail to fold into their physiological configuration and lose their normal function. 
When this occurs, the protein undergoes a misfolding process and eventually converts into 
intractable aggregates, of which the most typical examples are amyloid fibrils. The diseases 
characterised by amyloid plaques formations are several and vary from neurodegenerative 
disorders, such as AD, to metabolic conditions, such as T2D. Increasing evidence suggests a link 
between T2D, mainly characterised by hyperglycaemia (high blood glucose) and AD, which 
causes a progressive loss of brain cells that leads to memory loss. These two diseases affect very  
Introduction 
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different parts of our body but may have a common aetiological trigger. The molecular mechanism 
of these diseases’ pathology is still area of contention. 
The molecular mechanisms of amyloid formation of glycated aggregation-prone peptides remain 
unknown. I planned to clarify how glycation is involved in the self-assembling of Abeta and IAPP 
using biophysical and structural approaches. The chosen glycating agent was methylglyoxal 
(MGO), a three-carbon atom dicarbonyl metabolite obtained from glucose glycolysis, highly 
reactive towards free amino groups of proteins producing advanced glycation products (42,141). 
I used several biochemical and biophysical techniques ranging from fluorescence and CD 
spectroscopy to AFM and NMR. Mass spectrometry was employed to map the glycation reaction 
sites of the peptides. By means of fluorescence-based assays, glycation and aggregation kinetics 
were followed at the same time. The occurrence of glycation was confirmed by the formation of 
the fluorescent argpyrimidine and aggregation was followed by ThT-binding assays, where the 
enhanced fluorescence corresponded to amyloid-like structure formation. Circular dichroism and 
nuclear magnetic resonance revealed the peptides secondary structure variation upon glycation. 
Finally, I evaluated the morphological effects of glycation on amyloid fibrils by atomic force 
microscopy. 
 
An important output of this study was to find commonalities and differences between AD and 
T2D, two disease that have been treated very separately so far. The outcome of the work here 
presented could represent a little piece of a bigger puzzle which may help with the identification 
of a new target and novel approaches to these two diseases. By identifying the common cause of 
AD and T2D, the final aspiration is to improve the age of risk diagnoses, with subsequent effect 
upon patient quality of life and social and economic impact. 
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3. Techniques employed  
3.1. Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy is a widely-used method to gain low-resolution structural 
information about proteins and peptides in solution (142). In particular, it is frequently used to 
determine protein and peptide conformations and conformational changes, and it has been 
employed to characterise the secondary structure of all peptides produced in this study. 
 
Circularly-polarised light consists of an electric and a magnetic field, perpendicularly oscillating. 
The electric field does not change its strength but only its direction, in a rotary fashion, so that the 
tip of its vector describes a helix along the direction of propagation (Fig. 15 A). Circular dichroism 
results from the interaction of a chiral chromophore with circularly polarised light and measures 
the difference between the absorption of left-handed circularly polarised light (Lcp) versus right-
handed circularly polarised (Rcp) light. The absence of a difference yields an absence of CD 
signal, which is indicative of the absence of a regular structure; any difference, positive or 
negative, results in variation of the absorption of the light and a consequent positive or negative 
intensity signal in the CD spectrum.  
 
When the left and right circularly polarised components are in-phase with equal amplitude and 
wavelength, the superimposition of their vectors results in a line. This is what happens before the 
beam passes through the sample in a CD spectrometer. When circularly polarised light hits an 
optically active compound in solution, for example a peptide with a definite structure, the beam 
is perturbed by an asymmetric sample, the two circularly polarised components (L and R) will be 
absorbed differently, and the projection of their vector will describe an ellipse, rather than a line. 
The rotation angle θ is defined as: 
θ = 
πC 
(εL - εR) / l 
The projection of the field vector defining the ellipse can be found in figure 15 A. 
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Figure 15. A. Ellipse described by the left and right polarised components when perturbed by an 
asymmetric chromophore. Red arrow (EL): field vector of left polarised light. Green arrow (ER): field 
vector of right polarized light. Blue arrow: projection of the superimposed vector, describing the ellipse. 
Θ is the degree of optical rotation. B. Characteristic CD spectra of alpha-helical (green), beta-sheet (red) 
and random coil (black) conformations.  
 
Peptides and proteins are ideal molecules to be studied by circular dichroism, because they consist 
of chiral amino acids connected via peptide bonds, which serve as chromophores and interact with 
the beam of light. The peptide bond, or amide bond, most efficiently absorbs light at wavelengths 
shorter than 250 nm. To gain information about the secondary structure of a certain peptide, the 
result of CD spectroscopy, the CD spectrum, must be considered to be a series of bands 
corresponding to different electronic transition states, from the ground state to an electronically 
excited one. In peptides and proteins, the two characteristic transitions are the π-π* transition, 
occurring at 190 nm, and the weaker n-π* transition, at 210 nm. The singularity of the hydrogen-
bond network, characteristic of each secondary structure, results in different CD spectra, as shown 
in figure 15 B. 
 
In nature, proteins are generally composed of more than one type of secondary structure and the 
corresponding CD profile is a proportional combination of their contributions. The CD spectra of 
a certain peptide or protein can be deconvoluted as the sum of the α-helix, β-sheet and random 
coil contributions: 
CDprotein = AXα-helix + BXβ-sheet + CXrandom coil 
where X represents the contribution of each secondary structure to the global spectrum, and A, B 
and C are the data points corresponding to the ideal spectra of the three conformations. Strong 
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minima at 222 nm and at 208 nm, together with an intense maximum at around 192- 195 nm, are 
representative of an α-helix, since it correlates with the hydrogen-bonding environment of this 
conformation; the β-sheet conformation is represented by a single minimum between 210 nm and 
220 nm, and a positive peak of similar intensity between 190 nm and 200 nm. Many denatured 
proteins and peptides, oligopeptides and polypeptides possess a CD spectrum typical of a random 
coil, with a single minimum near 195 nm and very weak positive, broad bands between 220 nm 
and 230 nm. Such a CD profile means that their building blocks are still bonded together but there 
is no well-defined hydrogen-bonding network between them. The interpretation of a CD spectrum 
is not always straight forward, although it is generally easier for short model peptides.  
 
3.2. Thioflavin T-binding assay 
Thioflavin T (ThT) is a dye extensively used to monitor amyloid formation over time in a 
fluorescence-dependent way. ThT was firstly described as a potent fluorescent marker of amyloid 
like-structures in 1959 by Vassar and Culling (32). In particular, it was pointed as far superior to 
other routine amyloid dyes such as Congo red or methyl violet (32). In the late 1980s the ThT 
fluorescence spectra and binding properties were characterised by LeVine and Naiki et al. (143-
147). It was described that, upon binding to amyloid fibrils, or to structures containing cross-beta 
bonds, ThT shows a significant shift of its emission and excitation maxima (143,145). 
 
Figure 16. A. Chemical structure of ThT. B. The two planar segments of ThT whose mutual rotation 
defines chirality are also shown. Modified from (32). 
 
ThT molecule consists of a benzylamine and a benzathiole ring connected through a carbon-
carbon bond (Fig. 16 A). When free in solution, a low energy barrier allows for free rotation 
around this C-C bond (Fig. 16 B), feature which quenches the excited states of the molecule when 
hit by a photon beam. In these conditions, the maximum reported excitation and emission 
wavelength for ThT are 385 nm and 445 nm, respectively (Fig. 17) (143,146). 
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Figure 17. A. Characteristic increase in ThT upon binding to amyloid fibrils and low fluorescence 
emission for free ThT. Modified from (6). 
 
When ThT binds to cross-beta type structures, such as in amyloid aggregates, the dye emits 
enhanced fluorescence and also a characteristic red shift of its emission spectrum is observed 
(148). As it is generally believed, the significant increase in ThT fluorescence is caused by the 
selective immobilisation of the molecule in a conformer which better maintains the excited state. 
(149). Upon binding to amyloid-like structures, the rotation around the carbon-carbon bond 
between the benzylamine and benzathiole rings of ThT becomes limited. In this conformation, 
the spectral characteristics of ThT change: its excitation maximum moves from 385 nm to 450 
nm and its emission maximum from 445 nm to 485 nm (143,145).  
 
The position in which the ThT becomes “blocked” seems to be in between the sheets of a cross-
beta-rich structure and the more abundant the cross-beta structures, the higher the intensity of the 
ThT emission bond to them. 
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Figure 18. A. The common structure of fibrils and a structural rationale for fibril-ThT interactions. Cross-
beta structure of amyloid fibrils (right), formed from layers of laminated beta sheets (6,150). B. “Channel” 
model of ThT binding to fibril-like beta sheets. ThT is described to bind along surface side-chain grooves 
running parallel to the long axis of the beta sheet. C. Crystal structure of ThT bound to acetylcholinesterase. 
(PDB 2J3Q). Modified from (151). Acetylcholinesterase is shown in cartoon representation in grey. All 
residues within 4 Å of ThT are shown as red sticks, except for Tyr121, which is omitted for clarity. The 
aromatic residues (Tyr and Trp) forming ThT-binding surfaces are labelled. The carbon, nitrogen and 
sulfur elements of ThT are in lavender, blue, and yellow, respectively. 
 
 
A large number of structural models on the process by which ThT binds to amyloid fibrils have 
been suggested. The fact that ThT binds to fibrils originated by different proteins, regardless of 
their amino acid sequences, strongly supports the theory suggesting that ThT recognises a 
structural feature common among fibrils. The ThT-binding site could be the surface of the cross-
beta architecture.  
 
The cross-beta architecture is characterised by laminated beta sheets whose strands run 
perpendicular to the long-axis of the fibril (Fig. 18) (6,150). This beta-rich composition produces 
the characteristic strong reflections at about 4.7–4.8 Å and 10–11 Å observed in X-ray diffraction 
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experiments of amyloid fibrils, which are interpreted as the strand spacing within and between 
beta-sheet layers, respectively (Fig. 18) (150,152). 
 
The cross-beta framework of fibrils (Fig. 18 A) is characterised by a characteristic adjustment of 
side-chains called “cross-strand ladders”, oriented between the beta-strand layers (Fig. 18 B) 
(153).  In amyloid fibrils, the distribution in rows of the cross-strand side-chains occur irrespective 
to the peptide sequence and these side chains form extended channel-like motifs along solvent-
exposed surfaces of fibrils. As a result, these channel-like pockets could be the binding site of 
linear dyes such as ThT. This hypothesis is described as the “channel model”. 
 
Another example is the “self-association model”, which considers the self-association of ThT at 
the centre of its theory. The ability of ThT to self-associate into micelle was recorded in few 
occasions, but the critical micelle concentration (CMC) is still under debate (6,154-156). The 
estimated CMC by Khurana et al. is 4 µM (156), whereas subsequent reports identified it around 
30 µM (154). As the ThT concentration commonly used for the binding assay is around 10-20 
µM, under these conditions it should not be possible to incur into micelles formation. 
 
To date, none of the possible models can adequately describe the chiral feature of ThT bound to 
amyloid fibrils (149,157) nor its propensity to bind parallel to the long axis of the fibrils (158). In 
addition, investigation on ThT binding cooperativity reported that independent ThT molecules 
often bind at a single type of site (146). Whereas the self-association model could give 
explanations about the promiscuous ability of ThT binding partners, it is nevertheless 
contradictory with several recent works describing specific molecular interactions of ThT with 
the surface of the cross-beta architecture of fibrils (6,159,160). 
 
Despite its demonstrated utility as an amyloid stain, substancial concerns over potential cross- 
reactivity of ThT led to several important studies investigating its specificity. In particular, ThT’s 
ability to bind hydrophobic pockets in globular proteins has been extensively characterised. The 
crystal structure of ThT bound to acetylcholinesterase demonstrated that the dye binded in a site 
formed primarily of α-helices, in striking contrast to cross-β fibrils (Fig. 18 C) (151). 
Interestingly, nearly all contacts with ThT were mediated by aromatic residues in the binding 
pocket, including extensive π-stacking with Tyr and Trp.  
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ThT has also been shown to bind to a hydrophobic pocket of human serum albumin with 
comparable affinity to many drug-like molecules (161). ThT’s capacity to interact with 
hydrophobic pockets in non-fibrillar proteins may rise concerns about its binding selectivity. For 
this reason, several controls should be carried out to verify that ThT does not stain the starting 
materials when used as a fibrillisation reporter, especially in cases of fibrils formed from 
associations of globular proteins.  
 
In conclusion, the molecular mechanism underlying the ability of ThT to recognise diverse types 
of amyloid fibrils and potential cross-reactivity of ThT with hydrophobic pockets in non-fibrillar 
proteins cannot propose ThT as the ideal tool to selectively staining and identifying amyloid 
fibrils. 
 
Although ThT may not be the perfect tool to study amyloid formation, it has been one of the most 
widely used dyes for monitoring amyloid formation since the 1960s. Further research into the 
molecular mechanism of ThT interactions with fibrils are required to fully understand amyloid 
formation, kinetics, structure, and pathogenesis. Complementary techniques can be taken in 
account to identify and confirm cross beta binding such as X-ray diffraction. 
 
3.3. Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique employed to identify the molecules by 
measuring their mass-to-charge ratio. MS works by ionisation of the analyte, which produces gas-
phase charged species. In protein analysis, the two most common methods of ionisation are 
matrix-assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI). For the 
analysis of large molecules such as proteins, peptides and DNA, mass spectrometry with MALDI 
is the standard method. Generally, the type of a mass spectrometer most widely used with MALDI 
is the TOF (time-of-flight mass spectrometer), measuring the time it takes for the molecules to 
travel a fixed distance. 
 
MALDI is a technique that involves diluting the protein in an organic solvent solution, in most 
composed of a small organic acid absorbing in the UV region such as acetonitrile. Such prepared 
sample is then deposited on a stainless-steel matrix. By deposition on a MALDI sample plate and 
by subsequent drying, crystallization of the protein occurs on the matrix. This plate is then inserted 
into a mass spectrometer and a pulsed UV-emitting laser is directed to the sample. Ionisation 
occurs by photon bombardment with minimal fragmentation. 
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In contrast to MALDI, ESI produces ions by applying a strong electric field to a liquid to create 
an aerosol. This type of MS is particularly useful when analysing proteins and peptides, since it 
overcomes their propensity to fragment during ionization. Moreover, both MALDI and ESI are 
often coupled with liquid chromatography to separate the peptides in complex mixtures before 
ionisation.  
 
3.4. Liquid chromatography–mass spectrometry  
Liquid chromatography–mass spectrometry (LC-MS) is an analytical chemistry technique that 
combines the physical separation power of high-performance liquid chromatography (HPLC) 
with the mass analysis capabilities of mass spectrometry (Fig. 19). While liquid chromatography 
isolates the individual component from a mixture, mass spectrometry provides the structural 
identity of the sample. The combined technique derived from the combination of MS and HPLC 
is commonly known as LC-MS. The use of LC-MS reduces experimental error and improves 
accuracy.  
The mobile phase in a liquid chromatography system is a pressurised liquid, while the MS 
analysers commonly operate under vacuum. As it is not possibile to directly pump the eluate 
coming from the column directly into the MS source, the LC-MS system requires an extra 
interface that efficiently transfers the separated components from the liquid chromatography 
column into the MS ion source. Overall, the interface is a mechanically simple part of the LC-MS 
system that has the role of desolvation, to remove the solvent from the eluate, and ionisation, to 
generate the gas phase analyte ions. 
 
Figure 19. Schematic diagram of liquid chromatography–mass spectrometry. After elution through a 
HPLC, the mass spectrometer separates the ionised molecules that have been transferred to the gas phase. 
Ions are then separated according to their mass and charge (m/z) in the mass analyser.  
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3.5. Atomic Force Microscopy  
Developed in 1986 by Binning, Gerber and Quate, as a collaboration between IBM and Stanford 
University, AFM reconstructs the three-dimensional morphology of a sample on a flat surface by 
monitoring distance-dependent interaction forces between a sharp probe and the sample (Fig.20 
A) (162).  
 
The probe used is a microfabricated sharp tip, typically less than 5 μm tall and often less than 10 
nm in diameter at the apex. The tip is attached at the free end of a flexible cantilever that is usually 
100–500 μm long. (Fig.20 B) The probes can be made of silicon or silicon nitride, and they can 
have pyramidal or conical shape (163).  
 
AFM scanners are made from piezoelectric material, which expands and contracts proportionally 
to an applied voltage. The scanner is designed by integrating five independently operated 
piezoelectrodes, into a single tube, forming a scanner which can manipulate samples and probes 
with extreme precision in vertical (Z) and horizontal (X, Y) directions. In some models (e.g. 
MultiMode SPM) the scanner tube moves the sample relative to the stationary tip, which is the 
most common mode. In other models (e.g., STM, Dimension Series and BioScope SPM’s) the 
stationary part is the sample, whereas the scanner moves the tip (163). The sample lies on a 
piezoelectric tube, made of piezoelectric ceramic, that elongates or contracts depending upon the 
polarity of the voltage applied (Fig. 20 C). 
 
 
Forces between the tip and the sample surface cause the cantilever to bend and deflect. The 
cantilever deflections are measured by a photodiode detector and processed by a computer to 
generate a map of surface topography (163).  There are different tip-sample interaction forces and 
they can be identified as repulsive and attractive interactions. In the absence of external magnetic 
and electric fields, short-range repulsive interactions are dominant. Pauli repulsion take the lead 
at a close tip-sample distance ranging from sub nanometre to a few nanometres, while attractive 
forces such as van der Waals interactions and capillary forces prevail at distances above few 
nanometres. In addition, in both regimes, viscoelastic and adhesive interactions can also be 
present (22,164). 
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In other words, the forces between the tip and sample are directly influenced by the separation 
distance. As the tip and the sample are gradually closer, their atoms start to weakly attract each 
other. These attraction forces increase until the atoms are as close that their electron clouds cause 
repulsion forces. This electrostatic repulsion progressively weakens the attractive force as the 
separation continues to decrease.  
 
An AFM can operate in static (contact) or dynamic mode (tapping or non-contact mode) (Fig. 20 
D). The static mode, also called contact mode, operates by scanning a tip attached to the end of a 
cantilever across the sample surface while monitoring the change in cantilever deflection with a 
split photodiode detector. The elastic deformation of the cantilever caused by the tip-sample 
repulsion can be directly measured. In particular, deflection of the cantilever is measured using 
an optical lever method, by means of a laser beam focusing on the back of the cantilever. Thus, 
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Figure 15. A. Simplified representation of an atomic force microscope. The atomic force microscope 
builds up the three-dimensional morphology of a sample on an atomically flat surface by raster-scanning 
a small tip over the sample surface. The tip is attached at the end of a cantilever, which creates a specific 
deflection. The characteristics of the deflection is dependent on the characteristic according to the features 
that the tip encounters on the sample surface and it is detected with an optical lever (red line): a laser beam 
reflecting off the end of the cantilever onto a segmented photodiode detector. B. Electron micrograph of a 
used AFM cantilever. Image width ~100 µm (165). C. The effect of applied voltage on piezoelectric 
materials, which can expand or contract in presence of a positive or negative magnetic field (161).  D. 
AFM operation modes. Contact mode, when scanning the is constantly in contact with the sample surface. 
Tapping mode when the tip is intermittently brought in contact with the sample. Modified from (166). 
 
These images of the sample are obtained by maintaining a constant deflection and hence force, of 
the cantilever during the scanning. The cantilever deflection x is proportional to the interaction 
force F, as described by the Hooke's law F = k⋅x, where k is the cantilever's spring constant. When 
the laser spot moves on the detector, the feed- back system reacts by extending or retracting the 
piezo actuator along the Z axis to compensate deviation of the cantilever deflection from the 
chosen set point.  
 
Two main dynamic modes can be identified: tapping mode, in which the tip is intermittently 
brought in contact with the sample and non-contact mode, where there is weak tip-sample 
mechanical contact. 
 
The tapping mode is most commonly used for biological samples (162) and it operates by 
scanning a tip attached to the end of an oscillating cantilever across the sample surface, so the tip 
lightly taps on the sample surface during scanning, touching the surface at the bottom of its swing. 
The cantilever is oscillated with a frequency much faster than the lateral scan and with an 
amplitude ranging typically from 20nm to 100nm. 
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The interaction forces between tip and sample produce nonlinear dynamics. The movement of the 
cantilever is caused by both the nonlinear tip-sample interaction force and the sinusoidal driving 
force (Fig. 22). The scanner position at each (x,y) data point to maintain a constant setpoint 
amplitude is processed by the computer to obtain the topographic image of the sample surface.  
 
AFM operation in contact mode can damage or distort some soft biological samples. On the other 
hand, very soft and fragile samples can be imaged successfully in tapping mode by oscillating the 
tip over the sample, and by making only brief intermittent contacts. For this reason, tapping mode 
is the operation mode chosen in this thesis to identify and characterise the morphological different 
oligomeric populations of aggregation-prone proteins. 
 
 
Figure 16. Feedback operation to measure sample topography. A. Deflection of the AFM tip in contact 
mode. Note that the optical lever gives a signal proportional to an error signal. The control signal being 
sent to the actuator is a good, albeit band-limited, representation of the surface. B. Deflection of the AFM 
tip in tapping mode. In tapping mode, the drop-in oscillation amplitude results in the feedback loop raising 
the position of the Z scanner, which restores the oscillation amplitude. A rise in oscillation amplitude 
results in the controller lowering the position of the Z scanner. The control signal can then be used as a 
representation of the surface. Image adopted from (167). 
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3.6. Nuclear Magnetic Resonance  
Nuclear magnetic resonance (NMR) was first described and measured in molecular beams by 
Isidor Rabi who was awarded the Nobel Prize in physics for this work in 1944. Two years later, 
Felix Bloch and Edward Mills Purcell demonstrated that nuclear magnetic resonance could be 
detected also in condensed phases, i.e. liquids and solids, a discovery for which they shared the 
Nobel Prize in physics in 1952. In the last few decades NMR has been used routinely to investigate 
chemical compounds, proteins and complexes. The method relies on intrinsic spin properties of 
nuclei.  
 
Discovery of nuclear magnetic resonance, in turn, originated nuclear magnetic resonance 
spectroscopy, the most powerful analytical spectroscopy for chemistry and biology so far. The 
core of this spectroscopy resides in the possibility of obtaining information on the chemical 
environment of specific nuclei from information about the nuclei. 
Protons and neutrons have an intrinsic angular moment as if spinning on their axes. Angular 
moments can be associated to a magnetic moment. In many atoms the spins of nuclear particles 
are paired, with the consequence that the nucleus of the atom has no overall spin, but in some 
atoms, notably the obvious case of 1H or 13C, the nucleus has an overall spin.  
According to the rules of quantum mechanics a nucleus of spin I has 2I+ 1 possible orientations. 
Thus, nuclei with spin 1/2 which are those most commonly used in NMR spectroscopy, e.g. 1H, 
13C and 15N, will have two possible orientations. When the nuclei are not immersed in an external 
magnetic field, the two orientations have equal energy. If a magnetic field is applied, the energy 
levels separate, with the one along the external field of lower energy. 
The lower energy level will be populated with a tiny excess of nuclei than the higher level. 
Irradiation with electromagnetic radiation in the radio frequency range can equalise the 
populations giving rise to a resonance signal. 
However, the actual magnetic field experienced by a nucleus is slightly different from the external 
magnetic field because the nucleus is shielded by local electron density originating from chemical 
bonds. This difference gives rise to chemical shifts that are typical of different chemical groups. 
Chemical shifts are generally expressed in units of parts per million (ppm) with respect to the 
frequency of a reference compound. 
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The chemical shift yields information about the structure of molecules. The classical example 
from the early days of NMR spectroscopy is the proton-NMR (1H NMR) spectrum of ethanol. 
Instead of a single proton resonance it is possible to observe three distinct signals for the methyl, 




Figure 17. 1D 1 H NMR spectrum of ethanol with typical chemical shift differences among groups and J-
coupling splittings. Ethanol chemical structure is displayed on the top left.  
 
Additional information for structure determination arises from the so-called J-coupling between 
NMR nuclei. J-coupling arises from the interaction of spin states via chemical bonds and leads to 
the splitting of NMR signals. Coupling yields detailed information on the connectivity of atoms 
in a molecule. 
 
A great improvement in NMR spectroscopy was the introduction of multi-dimensional 
techniques. The first such spectra were two-dimensional (2D NMR), a set of methods in which 
data are plotted in a space defined by two frequency axes. Among 2D NMR spectra, total 
correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) are 
noteworthy. TOCSY gives information on connections via coupling and NOESY gives 
information on connections through space.  
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The TOCSY spectrum contains a diagonal and cross peak. Diagonal peaks have the same 
frequency coordinate on each axis and correspond to the peaks in a 1D-NMR spectrum whereas  
the cross peaks indicate couplings between pairs of nuclei, such as mutliplets, corresponding to 
correlations through bonds. An example of 2D TOCSY spectrum of 2,3- dihydrofuran is displayed 
in figure 23. The molecule 2,3- dihydrofuran shows resonances at d 2.6, d 4.2, d 4.9, d 6.2 ppm.  
 
2D NMR spectroscopy provides much more information about molecular structure than 1D NMR 
and is particularly useful for molecules, such as proteins, that are too complicated to study with 
1D NMR. 
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Figure 18. 2D TOCSY spectrum of 2,3- dihydrofuran, 1H NMR spectrum is displayed on the top and left 
side of the 2D TOCSY spectrum. 2,3- dihydrofuran chemical structure is reported on the top left with 
numbers indicating the hydrogens reported on the 2D spectrum. Modified from (168). 
 
3.7. Arginine as glycation site model 
Glycation can occur on N-terminal amino acid groups, arginine, lysine and histidine residues, of 
proteins. Among the possible glycation products, the arginine-derived one (argpyrimidine) can be 
detected thanks to a fluorescent assay. For this reason, the amino acid arginine was used as a 
model to screen different glycation conditions in phosphate buffer at 37 °C. The fluorescent 
emission wavelength was screen from 360 nm to 600 nm maintaining excitation wavelength at 
320 nm on a sample containing 500 µM arginine incubated with 100-fold ratio MGO in 
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phosphate-buffered saline (PBS). Glycine and MGO were employed separately in the same 
conditions as negative control.  
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4. Material and Methods 
4.1 Sample production 
Abeta peptides (1-40 and 1-42) were purchased from rPeptide Inc (catalogue no. A1153-1 and 
A1163-1) as recombinant peptides. The peptides arrived lyophilised with 97% purity as 
determined by mass spectrometry and they were stored at -20°C until use.   
 
Full-length IAPP peptide was obtained from Peptide 2.0 Inc with 98.43% purity and from 
Eurogentec with 95% purity. The peptide arrived lyophilised and was stored at -20°C until use. 
The sample contained the physiological modifications, such as the 2-7 disulfide bridge and C-
terminal amidation as determined by mass spectrometry and reverse-phase HPLC. 
  
The purchased peptides (1 mg) were always treated under strong acidic conditions with pure 
trifluoracetic acid (TFA), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) or a combination of both to 
dissolve pre-existent fibrillar aggregates to reach the concentration of 1 mg/mL (87). 
 
Abeta peptides were treated with a combination of these acids. Abeta variants were firstly 
incubated in TFA for one hour at room temperature and then ultrapure water was added to reach 
10% (v/v) TFA concentration. After complete TFA removal by means of freeze-drying, Abeta 
peptides were dissolved in HFIP, which was removed by freeze-drying.  
 
For IAPP, the treatment was carried out with one acid at a time. In particular, the choice of acid 
for the sample preparation was determined by the effect of the solvent on the peptide secondary 
structure (see in chapter “Results - IAPP aggregation studies”). The sample was mixed vigorously 
and visually inspected for efficient solubilisation. After one-hour incubation at room temperature 
in acid solution, the solution was diluted in ultrapure water and up to 10% (v/v) TFA and freeze-
dried overnight in aliquots. This protocol allows dissolving possible aggregates and pre-formed 
aggregates and thus obtaining better reproducibility. The pre-treated protein was dissolved in PBS 
to a desired concentration. The glycated proteins were obtained by adding MGO in molar excess 
and the mixture was incubated at 37 °C. 
 
4.2 Methylglyoxal preparation 
Methylglyoxal (MGO) employed in glycation assay came either from a solution in ~40% water 
purchased from Sigma Aldrich (CAS number 78-98-8) stored at 4° C or from a solution prepared 
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in house. High purity MGO was prepared from 2.27 mmol methylglyoxal 1,1-dimethyl acetal 
(also called pyruvaldehyde dimethylacetal) purchased from Sigma Aldrich (CAS number 6342-
56-9) by acid hydrolysis using 5% H2SO4 in phosphate buffer, at 100°C for 25 min as reported 
(169). The acid hydrolysis method is quite reproducible. Purity and stability of the obtained MGO 
was verified by 1H NMR (Bruker advance 700 MHz).  
 
 Scheme 1. Acid hydrolysis of methylglyoxal 1,1-dimethyl acetal resulting in MGO. The reaction occurred 
in a solution of 5% H2SO4 in water at 100 °C and it was completed after 25 minutes 
 
 
4.3 Fluorescence spectroscopy 
Aggregation and glycation kinetics were followed by means of spectrofluorometric assays, using 
a FLUOstar OMEGA Lite instrument and a Jasco FP 6600 spectrofluorometer. Before each assay, 
the Abeta40, Abeta42 and IAPP peptides were prepared as previously described. To exclude any 
secondary effect of DMSO on the aggregation kinetics various concentrations of DMSO (1-10%) 
were screened and the concentration of 2% was chosen. Aggregation assays were performed in a 
Greiner UV-clear 96-well plate. Firstly, a 500 µM protein stock was prepared by adding pure 
DMSO  to the lyophilised sample. Secondly, the protein was diluted from the DMSO stock to 10 
µM in PBS pH 7.4, added with 20 µM ThT, in the presence and the absence of MGO (final 
concentration 1 mM), to obtain peptide:MGO ratios from 1:0 to 1:200. The temperature was set 
at 37 ˚C and the readings were performed every 15 minutes, setting the excitation wavelength at 
440 nm and the emission wavelength at 485 nm. The plate was left quiescent between 
measurements and shaken for only 1 second before each reading. Glycation kinetics was followed 
using the same conditions as for the aggregation assays, but the reaction mixture did not contain 
ThT. The excitation wavelength was set to 320 nm and the emission wavelength to 405 nm. In 
both experiments, every condition was repeated at least 4 times and the results were normalised 
according to the corresponding blank and expressed as percentage. 
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4.4 Circular dichroism spectroscopy 
Far-UV CD spectra were recorded in the range 200–260 nm on a Jasco J-1100 spectropolarimeter 
(Jasco, Essex, UK), equipped with a temperature control system, using a 1 mm quartz cuvette, 
using a peptide concentration of 10, 20 and 60 µM in 20 mM sodium phosphate, 15mM NaCl. 
Raw spectra were corrected for buffer contribution. The scanning speed was set to 200 nm/min, 
digital integration time to 1 sec, and the temperature to 37 °C for all experiments. To ensure 
reproducibility, all experiments were repeated at least three times on at least two different batches 
of peptides. 
 
4.5 Identification of the reactive glycation sites by mass spectrometry  
Mass spectra of both glycated and non-glycated Abeta42 were acquired by our collaborator 
Fabrizio Dal Piaz at the University of Salerno (Italy) using a MALDI-TOF Micro (Waters) 
instrument operating in reflectron mode. Mass calibration was carried out using a mixture of 
peptides obtained by proteolytic digestion of bovine serum albumin (BSA) with the bovine 
protease trypsin. The peptide underwent cysteines reduction and carbaminomethylation; after that 
it was digested overnight by trypsin at 37 °C while stirring. The digested fragments were analysed 
by nano-LC-MS using an Orbitrap XL instrument (Thermo Fisher Scientific) supplied with a 
nano-ESI source coupled with a nano-ACQUITY capillary UPLC (Waters). A capillary BEH C18 
column (0.075 x 100 mm, 1.7 µm Waters) was used to separate the petide before ionisation. The 
solvent mixture employed as mobile phases was aqueous 0.1% formic acid (A) and acetonitrile 
containing 0.1% formic acid (B). Peptides elution occurred through a 45-min gradient from 5 to 
50% B at a flow rate of a 300 nl/min. Mass spectra were collected over a 400 to 1800 m/z range. 
 
4.6 Measurements of the fibre morphology 
Atomic force microscopy (AFM) was carried out on samples pre-treated as for ThT-binding assay 
and dissolved in an appropriate volume of PBS to obtain a concentration of 100 µM. They were 
loaded onto freshly cleaved mica and incubated for 5 min at room temperature. The excess of 
liquid was dried off from the mica and rinsed with a gentle flux of filtered mq-H2O. Samples were 
then incubated at 37 °C and images were acquired at different time points. Height peak force error 
images were obtained on a Bruker Multimode 8 microscope with a Nano scope V controller 
(Bruker UK Ltd., Santa Barbara, CA). Image data were acquired operating in peak force tapping 
mode using ScanAsyst Air cantilevers (115-µm nominal length, 25-µm nominal width, nominal 
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spring constants of 0.4 newtons/m, and typical resonant frequencies of 70 kHz). The ScanAsyst 
probes have a 2-nm nominal tip radius of curvature. Image data were obtained at peak force 
frequency of 4 kHz and a line rate of 3 Hz at a resolution of 512 pixels/line. Different sample 
dilutions were applied according to image clarity requirements (1:10 and 1:100). After dilution, 
100 µl of sample was loaded onto freshly cleaved mica and incubated for 5 min at room 
temperature. The excess of liquid was dried off from the mica and rinsed with a gentle flux of 
filtered mq-H2O. 
 
4.7 Nuclear magnetic resonance spectroscopy (NMR) 
NMR spectra were recorded on a Bruker 700 MHz instrument at the Randall Division of 
Molecular and Cell Biophysics at King’s College London. IAPP was diluted in either 10mM (pH 
5.5) or 100mM (pH 7.4) sodium phosphate buffer, supplemented with 5% D2O, yielding a 
yielding a final protein concentration of 60 µM in each case. Experiments were conducted at 10°C 
and 37°C. The 1D spectrum was recorded and the 2D TOCSY (Total Correlation SpectroscopY) 
spectrum was obtained with 8 scans and spectral width of 11261 (x-axis) and 5630 (y-axis). To 
carry out the 1D, in each sample, 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) was added as 
internal standard, exhibiting minor peaks at 2.91 ppm, 1.75 ppm, and 0.63 ppm at an intensity of 
22% of the reference peak at 0 ppm in the proton spectrum. 
 
4.8 IAPP production 
The production of both rat and human isoforms was attempted. The rat isoform was initially used 
to test the expression and purification of IAPP, since this isoform is much less aggregation prone 
than the human one. 
 
4.8.1 Transformation of IAPP fusion protein  
IAPP coding region inserted into the pTXB1 plasmid from NEB was expressed in E. coli BL21 
(DE3) cells. The plasmid also contains the gene that confers ampicillin resistance to the cells. 
An aliquot of 15 µL of E. coli competent cells BL21 (DE3) was thawed at room temperature to 
carry out the heat-shock transformation. When the cells were evenly suspended, 100 ng DNA 
solution was added to the cells and gently mixed. After an incubation in an ice bath for 30 minutes, 
the cells were heat-shocked at 42°C for 90 sec and then transferred to an ice bath for 2 minutes. 
Then 500 µL of Luria-Bertani (LB) medium was added and the tube was placed in a 37 °C 
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incubator under shaking for 45 minutes. Finally, the cells were spun down at 1300 rpm for 2 
minutes and 450 µL of supernatant was removed in order to facilitate the resuspension of the cells 
in the remaining LB medium. A desired portion of the mixture was plated onto a LB-agar plate 
supplemented with 50 µg/ml ampicillin. The plates were incubated at 37 ° C overnight and the 
day after were grown in LB supplemented with ampicillin until they reached an optical density at 
600 nm (OD600) of 0.6. Glycerol stocks were made by mixing 200 µL of cells with 200 µL of 
sterile glycerol and frozen at -80°C. 
 
4.8.2 Expression of IAPP fusion protein 
All purification steps were carried out at 4°C and protein samples were stored on ice whenever 
possible unless otherwise stated. Affinity-columns were purchased from GE Healthcare, column-
based purifications were carried out on ÄKTApurifier systems from GE Healthcare.  
The starter culture was directly inoculated from a glycerol stock using a sterile loop and grown 
overnight at 37°C under shaking. Overnight cultures were diluted 1:50 in LB medium 
supplemented with 100 µg/mL ampicillin and shaken at 37°C, 120 rpm for 3 hours or until an 
OD600 of 0.7 was reached. 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) was added to 
induce over-expression and the cells were incubated overnight at 18°C under shaking. 
The following day, the cells were centrifuged at 4000 rpm, 4 °C for 20 min and the cell pellet was 
resuspended in elution buffer (20 mM Hepes pH 8.0, 0.1 mM EDTA, 50 mM NaCl, 2M Urea). 
25 mL of resuspension buffer were used per 1L cell pellet. The pellets were stored at -20°C. 
 
4.8.3 Purification of IAPP  
The protein purification process was adapted from Williamson et al (170) and Rodriguez, 
Camargo et al protocol (171).  
Bacterial pellets suspended in elution buffer were lysed via pulsed sonication for 5 min on ice (50 
sec duty cycle, output intensity 5) and the crude protein extract was cleared by centrifugation at 
5000 rpm for 15 min at 4 °C. The lysate was centrifuged at 12000 rpm for 30 min at 4°C. No 
lysozyme was added in this step to prevent degradation of the chitin beads. The cell lysate was 
purified by affinity chromatography using a chitin-bead gravity flow resin purchased from NEB. 
The chitin column (30 mL of chitin beads bed volume) was equilibrated with three column 
volumes of elution buffer. The lysate was loaded onto the column and left incubating at 4°C 
overnight to allow for optimal binding of the CBD to the beads. Then the column was washed 
with 15 column volumes of elution buffer to remove unbound proteins. The intein cleavage 
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reaction was initiated by addition of 60 mL of chitin buffer (elution buffer supplemented with 100 
mM DTT and 2 M ammonium bicarbonate). Ammonium bicarbonate in the buffer is required to 
yield amidation of the C-terminus (111). After elution of approximately 20 mL, the column flow 
was stopped, and the content was left under continuous rotation overnight at 4 °C. The protein 
was subsequently eluted with one column volume of chitin buffer, followed by 20 – 30 mL wash 
with the same buffer in order to collect residual cleaved protein. All the fractions containing the 
fusion protein leader-hIAPP were collected and run on SDS-PAGE. In order to regenerate the 
chitin column, the beads were washed with three column volumes of 0.3 M NaOH and three 
column volumes of water. The column was then stored in elution buffer with 0.02% sodium azide. 
Size-exclusion chromatography was used to separate the construct leader-IAPP from the uncut 
protein and from the intein-CBD product. Soluble protein was loaded onto gel filtration column 
(HiLoad 16/60 Superdex 75 pg) in gel filtration buffer (20 mM KH2PO4, pH 6.8) and fractions 
were collected during elution. SDS PAGE and silver staining were used to select the fractions 
containing pure IAPP. Precast 12% Bis-Tris protein gels for SDS-PAGE (Cat. N. NP0343BOX), 
NuPAGE MES SDS running buffer (20X) and Pierce silver stain kit (Cat. N. 24612) were 
purchased from Thermo-Fisher. The final product was then pooled, concentrated and stored at -
20°C.  
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5. Results - Abeta40 and Abeta42 
In this project, I investigated the effect of glycation, and its relation to protein aggregation using 
Abeta40 and Abeta42, the two main species observed in AD patients and IAPP, a peptide 
intimately associated with hyperglycaemia and T2D. 
Abeta peptides were always effectively disaggregated through a sequential treatment with the 
volatile solvents TFA and HFIP, as suggested by Zagorski  et al and extensively reported in the 
literature (87,172,173). Zagorski et al. presented a sequential treatment with TFA and HFIP to 
completely disaggregate the synthetic Abeta variants (172). After acid removal by freeze-drying, 
the pre-treated protein was dissolved in PBS at pH 7.4 in the presence or absence of MGO. 
 
5.1 Aggregation kinetics and glycation reaction optimisation 
To understand the contingent effect of glycation on the folding and aggregation properties of 
Abeta peptides, it was necessary to identify the ideal experimental conditions to follow both the 
processes, occurring simultaneously, in an independent way. To allow for all possible glycation 
sites of Abeta (lysine, N-terminus, arginine, histidine) to be potentially available to react with 
MGO, the aggregation process needed to be sufficiently slow. For this reason, I screened different 
buffer systems (phosphate buffer concentration, salt concentration) and peptide concentrations 
(ranging from 5 to 50 µM) and I investigated their effect on glycation reaction speed and protein 
self-assembly. Optimal conditions were identified using PBS at pH 7.4 (174). The ideal peptide 
concentration for following aggregation kinetics and glycation reaction within acceptable time-
frame was 10 µM. 
 
While aggregation kinetics could be investigated confidently with ThT-binding assay, identifying 
the glycation products required the employment of analytical techniques. However, it has been 
reported that the arginine on position five of Abeta peptides readily reacts with MGO to produce 
the AGE product argpyrimidine, which is an AGE product with spectrofluorometric properties 
(175-177). The other potential products at the N-terminus or on Lys16, such as CEL and CML, 
do not have appreciable fluorescence emission (177). For this reason, I decided to study the 
spectral properties of arginine when incubated with MGO, to verify whether the glycation reaction 
could be followed by monitoring formation of the fluorescent argpyrimidine. After optimisation, 
the addition of a 100-fold excess of MGO was shown to be necessary to obtain appreciable 
glycation. The selected MGO concentration is far from physiological but was employed to 
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accelerate an intrinsically very slow reaction and to follow any effects in an acceptable time 
interval (178). To investigate the formation of argpyrimidine, the excitation wavelength was set 
at 340 nm, according to literature, and the emission spectrum was acquired between 360 and 600 
nm (179). No significant fluorescence was recorded at time 0 and for the first 2 hours. An 
increasingly stronger fluorescence signal was detected between 4 and 42 hours with a plateau at 
24 hours. The maximum emission wavelength slightly shifted with time from 412 nm to 405 nm 
(Fig. 24). As a control, I also followed the emission of MGO by itself for the same time-frame. 
No significant fluorescence was observed (Fig. 24 B). In addition, to verify that the fluorescence 
emission spectra of the AGE formation at 405 nm was not affected by the emission spectra of 
ThT, I incubated 10µM Abeta40 and Abeta42 in the presence and in the absence of 1mM MGO 







Figure 19. Following glycation of arginine by fluorescence spectroscopy. A. Fluorescence emission 
spectra of arginine. B. Kinetics of glycation at 405 nm of arginine with amino acid:MGO ratio=1:100 and 
of MGO. In the kinetics, the variation of the emission fluorescence at 405 nm is proportional to AGEs 
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formation as a function of time.  C and D. Fluorescence intensity of ArgP at 405 nm formed in Abeta 40 
and Abeta42 in the presence and in the absence of MGO. This assay was carried out in the absence of ThT. 
The fluorescence emission spectra of the AGE formation at 405 nm was not affected by ThT. 
 
 
5.2 Study of the effect of glycation on Abeta40 and Abeta42 kinetics 
After pre-treatment with TFA and HFIP, Abeta peptides were dissolved in PBS, divided into two 
aliquots and incubated with or without increasing amount of MGO at 37 °C.  Kinetics of glycation 
and aggregation were investigated using a multi-well fluorescence plate reader, which allowed 
me to set multiple excitation and emission wavelengths at the same time. This was crucial to 
follow the two processes concomitantly on the same sample. I therefore set the excitation at 440 
nm and the emission at 485 nm to follow the aggregation kinetics with ThT, and I recorded the 
argpyrimidine formation by choosing an excitation of 320 nm and an emission of 405 nm. 
 
The fluorescence intensity of argpyrimidine formation on Abeta40 and Abeta42 at 405 nm 
steadily increased for around 24 hours, when the plateau was reached (Fig. 25 A, B), as suggested 
by the arginine model. For both peptides, the curve describing the glycation process is concave in 
shape and lacks a lag phase, indicating a reaction that takes place from time 0 and reached its 80% 
in the first 10 hours. 
 
ThT-associated fluorescence was employed to follow the aggregation kinetics of the Abeta 
peptides and verify whether the presence of at least one glycated amino acid (Arg5) could alter 
the speed of the process. The enhanced fluorescence of ThT when bound to amyloid-like 
structures is commonly used to monitor amyloid formation over time (6).  
 
As reported in the literature, Abeta40 displays slower aggregation kinetics compared to Abeta42 
(180,181). Both peptides describe a sigmoidal curve but the lag phase of Abeta40 lasts for around 
10 hours, while Abeta42 aggregates faster, with only few minutes of lag phase and with a plateau 
reached after 12 hours. Abeta40 needs ca. 18 hours to reach the plateau of its aggregation. Also 
worthy of notice, the glycation of Abeta40 mostly occurs during the lag phase of its aggregation, 
suggesting that the glycation sites may be better exposed at this stage. 
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At all tested peptide:MGO ratios of 1:50, 1:100 and 1:200 the kinetics obtained from the glycating 
peptides showed that glycation slows down the aggregation process of both Abeta40 and Abeta42 
(Fig. 25 C, D). The absence of a concentration-dependent effect could be explained by the 
saturation of glycation sites already at 1:50 ratio. For Abeta40, the presence of MGO further 
elongates the lag phase of a couple of hours, indicating that the glycation reaction may slow down 
the first nucleation process and that glycated species may be more conformationally constrained 
in their monomeric/oligomeric fold (182). Due to the very fast aggregation of Abeta42, a possible 
effect of glycation on the kinetics of aggregation is hard to estimate. However, glycation seems 
to limit the total amount or the growth of fibres of Abeta42 to 40% of its maximum, indicating a 
possible effect on the secondary nucleation (23). 
 
These results corroborated the hypothesis that glycation affects the Abeta peptides aggregation 
pathway not by completely abolishing the process but by slowing down the formation of either 
oligomeric or fully-mature aggregates.  
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Figure 20. Kinetics of glycation and aggregation for Abeta40 and Abeta42 at 10 µM. A and B. Kinetics 
of glycation of Abeta with a peptide:MGO ratio of 1:100 for Abeta40 and Abeta42, respectively. The 
kinetics are represented proportionally to the variation of the emission fluorescence relative to formation 
of argpyrimidine as a function of time. The fluorescence values were averages of three readings, 
normalised according to the corresponding blank and expressed as percentage. C and D. Kinetics of fibre 
formation of Abeta by itself and with an increasing ratio of peptide:MGO ratio for Abeta40 and Abeta42 
respectively. The fluorescence values are expressed as percentages and are shown as an average of the 
three readings. 
 
5.3 Effect of glycation on Abeta secondary structure  
The effect of glycation on the secondary structure of the Abeta variants was monitored at different 
time points by CD spectroscopy, a technique which can provide broad structural information on 
the secondary structural transitions of proteins. Following optimisation experiments, 50 µM 
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Abeta40 and Abeta42 were diluted in phosphate buffer (200 mM sodium phosphate) pH 7.4, with 
or without a 100-fold molar excess of MGO. CD spectra were acquired at 37°C at time zero and 
after six- and 12-hour incubation. The results of this investigation are reported in figure 26. 
 
CD spectra at different time points showed different degrees of ellipticity, but all peptides showed 
an initial pure random coil for Abeta40 and a mixture of beta-sheet and random coil conformation 
for Abeta42 at time 0. Abeta42, though, exhibits a higher beta-sheet content than Abeta40 at t0, a 
behaviour in agreement with the higher tendency of the longer peptide to aggregate faster (180).  
Abeta 40 and Abeta42 displayed a similar pattern, transitioning from a more random coil 
conformation to a richer in amount of beta-sheet structure already after six-hour incubation.  
 
Already after six hours, both Abeta variants displayed a CD profile typical of a purely beta-sheet 
peptide, with a negative band at 218 nm, but characterised by different degrees of ellipticity. The 
difference in terms of signal intensity could be explained by a higher degree of protein 
precipitation in Abeta42 sample, leading to a decrease of protein concentration in solution. In the 
presence of MGO, Abeta40 did not display an obvious conformational change: the CD spectrum 
obtained at t0 described a random coil conformation, where the minimum at 218 nm is almost 
absent. A slight curvature in the region between 215 nm and 220 nm can be observed after six 
hours, and this signal, probably reporting on an increment in beta content, is more pronounced 
after 12 hours incubation.  
 
Glycated Abeta variants showed a conspicuous amount of white flocculus precipitate visible at 
the naked eye at the bottom of the cuvette, suggesting a loss of solubility of the glycates species 
compared to the non-glycated (data not shown). This could be due to the formation of heavier 
aggregates or to the presence of MGO in the solution (data not shown).  Nevertheless, glycated 
Abeta40 never seems to fully lose its low-wavelength minimum associated with random coil. 
Abeta42, in the presence of MGO, showed a similar conformational transition to beta sheet as 
Abeta40, starting from a mixture of beta-sheet and random coil conformation. After six-hour 
incubation a very broad minimum in the beta-sheet region of 218 nm was the recognisable 
contribution of the transition from random coil to beta sheet. Full 12 hours had to pass before a 
complete transition towards beta sheet could be observed.  
 
CD spectra collected in the presence of 100-fold MGO showed that the Abeta conformational 
transition from random coil towards beta sheet-rich structures is delayed in both variants. In 
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Abeta40 the conformational transition delay is more pronounced than Abeta42, but this could be 
due to the slower aggregation process that Abeta40 undergoes (180). The higher aggregation 





Figure 21. CD spectra of the Abeta peptides in the presence and in the absence of MGO collected at 
different incubation time at a peptide concentration of 50 µM. Time 0 is displayed in red, six-hour 
incubation at 37° C in green, 12-hour incubation at 37° C in blue. DMSO was not employed. A. Abeta40, 
in the absence of MGO, the transition from random coil to beta sheet of Abeta40 during the fibrillation 
process is displayed. B. Abeta40 with a 100-fold molar excess of MGO. Its native random coil 
conformation is preserved over time. C. Abeta42, in the absence of MGO, showed a transition from mixture 
of beta sheet and random coil to pure beta-sheet conformation. D. Abeta42 with a 100-fold molar excess 
of MGO, its transition from random coil to beta sheet during the fibrillation process is displayed. The 
transition time is longer in the presence of MGO. Data expressed in ellipticity. 
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5.4 Identification of Abeta peptides glycation sites by mass spectrometry  
Spectrofluorometric techniques allowed me to confirm the occurrence of the glycation product 
argpyrimidine when Abeta40 and Abeta42 were incubated with excess of MGO. Nevertheless, as 
previously described, this is only one of the possible AGEs deriving from the glycation of these 
peptides. I therefore decided to identify all reaction products by MALDI/MS. MGO-glycation 
sites were identified on Abeta40 by Fica-Contreras et al. They demonstrated Lys16 was glycated 
four times faster than Arg5 (175). Since they identified the MGO glycation products on Abeta40 
I focused primarily on comparing these published results with the ones I obtained for Abeta42. 
 
After incubation of Abeta42 with MGO in phosphate buffer without additional salt (which would 
have interfered with the ionisation), three main species were observed, in addition to the unreacted 
peptide (Table 2). Note that the difference of one mass unit between the m/z values mentioned 
and the ones shown in figure 3 is due to the isotopic pattern: peaks related to ions with the same 
chemical formula can contain different isotopes and their particular pattern is associated with the 
relative abundance of the isotopes. The signal at m/z 4514.4 was associated to the unmodified 
peptide (Fig. 27 A, top), which has a theoretical molecular weight of 4514.1, and the signals at 
m/z 4586.5, 4594.5 and 4666.6 (Fig. 27 A bottom) confirm that glycation occurred. The ion at 
m/z 4586.5 was due to a mass increment of 72 Da; this ion could report on the formation of two 
possible species, arising from glycation at either the N-terminus amino group or at one of the two 
lysine side chains to form CEL (175,183). The formation of argpyrimidine from the glycation of 
Arg5 is demonstrated by the ion at m/z 4594.5 (mass increment of 81 Da). Furthermore, a minor 
species was detected (m/z 4664.6) whose mass exceeds that of free Abeta42 by 152 Da. This 
indicated the addition of MGO to both a lysine residue with the formation of CEL (mass increment 
of 72 Da) and to the arginine with the formation of argpyrimidine (mass increment of 81 Da). The 
additional peak detected in the non-glycated Abeta42 (m/z 4425.4) was tentatively assigned to the 
fragment 1–41, produced during the MS analysis by the laser-induced elimination of the C-
terminal alanine residue. 
 
To identify the exact glycation sites, it was necessary to subject glycated Abeta to trypsin 
digestion in order to generate smaller fragments, each including a single modifiable site (Fig. 28). 
Liquid chromatographic separation of the digestion products allowed to isolate the different 
species formed after glycation reaction, for subsequent MS analysis. Fragments obtained by 
enzymatic digestion were analysed by high-resolution LC-MS. Species of seven different 
molecular weights were detected (Table 4), four of which corresponding to portions of digested 
         
 81 
non-glycated Abeta42, demonstrating efficiency of digestion. The other three major ions were 
described with a molecular weight of 2033.903, 2714.259, and 3412.644. They corresponded to 
the glycated residues 1–16 with an argpyrimidine on position 5 (theoretical weight 2033.894, 
triply charged ion at m/z 678.968); to the fragment 6–28 with a CEL on either position 16 or 28 
(theoretical weight 2714.314, triply charged ion at m/z 905.786); and to the fragment 1–28 with 
both modifications at Arg5 and Lys16 (theoretical weight 3412.634, quadruply charged ion at m/z 
854.181) (Fig. 27 B). The presence of all four different species (unmodified peptide, double 
glycated peptide, glycated peptide on lysine and on arginine residue) suggests an equal reactivity 
of the two glycation sites demonstrates that there is no interference of the formation of one product 
on the other. 
 
To identify which of the two lysine residues was indeed glycated, I considered that the protease 
trypsin would have not been able to cut right after the Lys28 if this residue was modified. I 
therefore deduced that Lys16 was hosting the glycation product. These results demonstrated that, 
in addition to the formation of the argpyrimidine that could be followed by fluorescence 
increment, also Lys16 was glycated by MGO under these experimental conditions. 
         
 82 
 
Figure 22. MALDI/MS analysis of glycated and non-glycated Abeta42. A. spectra of Abeta42 (top) and 
glycated Abeta42 (bottom). Different species observed in the spectra were identified on the basis of their 
molecular weight (Table 1). B. High-resolution ESI spectra of tryptic fragments of glycated Abeta42. 
Triply-charged ion at m/z 678.968 (top) was generated by the fragment 1–16 carrying one argpyrimidine 
residue (theoretical molecular weight 2033.894). Triply-charged ion at m/z 905.786 (middle) corresponds 
to the fragment 6 –28 with one N-(carboxyethyl)-lysine (N-CEL) (theoretical molecular weight 2714.314). 
Quadruply-charged ion at m/z 854.181 (bottom) corresponds to the fragment 1–28 carrying both 
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Table 2. List of the main fragments of the trypsin-digested Abeta42 fragments identified by MALDI/MS 
analysis and their molecular mass. The difference of 1 mass unit between the values cited here and the 
figure is due to the isotopic pattern. 
 
Ion (m/z) Peptide Experimental MW Theoretical MW 
4425.5 
1-41 
Laser- induced fragment 
- - 
4512.4 1-42 4514.4 4511.3 
4584.5 1-42 [N-CEL] 4583.5 4583.3 
4592.5 1-42 [ArgP] 4591.5 4591.4 
4664.6 1-42 [ArgP – N-CEL] 4663.6 4663.4 
 
Table 3. High-resolution MS analysis of the digestion products obtained by trypsin-catalysed hydrolysis 
of glycated or non-glycated Abeta42. 
Ion 
(m/z) 
Peptide Experimental MW Theoretical MW 
Corresponding 
peptide 
637.298 1-5 636.291 636.287 Unmodified 
668.810 6-16 1335.604 1335.596 Unmodified 
663.348 17-28 1324.680 1324.666 Unmodified 
635.386 29-42 1268.756 1268.753 Unmodified 
679.302 1-16 [ArgP] 2039.906  2037.03 Glycated 
905.786 6-28 [CEL] 2714.335 2714.314 Glycated 
854.181 1-28 
[ArgP+CEL] 
3412.700 3412.675 Glycated 
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Figure 23. Abeta42 sequence segments produced for MS analysis. On the top the full-length sequence is 
displayed. The segments produced by trypsin digestion are 1-5, 6-16, 17-28, 29.42, 1-16, 6-28, 1-28. In 
red, amino acids identified as glycated. 
 
5.5 Analysis of the aggregate morphology of Abeta 
AFM was employed for the three-dimensional analysis of the Abeta40 and Abeta42 aggregates to 
study the effect of glycation on the morphology of the aggregates compared to the non-glycated 
forms. To obtain representative results, the assay was replicated three times each time acquiring 
up to ten images. The reported micrographs are representative of the species found.    
 
Abeta40 and Abeta42 were treated as for the ThT-binding assays and incubated for 24 hours at 
37 °C. The most abundant species identified for Abeta40 were amorphous oligomers of ca. 100 
nm. A few twisted fibres of variable length were also detected. These fibres had a height of 5.4–
8.2 nm and a diameter of 8–12 nm, depending on the helix pitch (Fig. 29 A, left panel). At the 
same time point and concentration, the glycated Abeta40 mostly formed multimers of similar 
shape and size of the ones formed by the non-glycated version, although they appear to be fewer. 
The longest of these oligomers were defined by a height of ca. 4.9 nm (Fig. 29 A, right). No fibre 
was identified. 
 
After 3 days of incubation, when both aggregation kinetics and glycation reaction are expected to 
be completed, the length of the twisted fibres formed by Abeta40 increased considerably (up to 
2.5 µm, taking into account fibre bending). The helix pitch was always constant and of 70 nm 
(Fig. 29 B and G, left) and the fibre diameter varied between 8.5 nm and 15.7 nm. At the same 
time point, glycated Abeta40 multimers developed into sporadic fibres with a similar morphology 
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compared to Abeta40 but with a smaller helical pitch (35 nm) and height (6.2-8.5 nm) (Fig. 29 B 
and G, right), indicating a possible different sterical arrangement of the beta sheets.  
 
At 7-day incubation time, the fibres of Abeta40 were found piled up together to give rope-like 
aggregates measuring 10–15 nm. Few single, long fibres still persisted but their number greatly 
decreased (Fig. 29 C, left). Glycated Abeta40 showed an increase in the number of fibres, but 
most of them were much shorter that the ones formed by Abeta40 and of constant diameter (11.8–
13.2 nm). A few, longer fibres were found (Fig. 29 C, right).  
 
In summary, glycation did not seem to substantially affect the morphology of the fibres formed 
by Abeta40. However, it seemed to reduce the amount of aggregates detected by AFM and the 
kinetics of their formation.  
 
A similar pattern was identified for Abeta42. Despite Abeta42 samples might look overall less 
aggregated at all considered time points, this phenomenon could be due to its precipitation. At 
day-1 of incubation, Abeta42 aggregated as short and thick fibrils with a wide range of diameters 
and ca. 14.2 nm heights (Fig. 29 D, left). At the same time point, the glycated Abeta42 mostly 
formed oligomers and only few rare larger aggregates, characterised by a smaller size (4.9 nm 
height and 15.0-nm diameter), were identified (Fig. 29 D, right). 
 
After 3 days at 37 °C, Abeta42 exhibited thick and twisted amyloid-like fibres of 0.8–1.6 µm in 
length, 9–15 nm in diameters, and 5.3–8.7 nm in height, depending on the helical pitch (Fig. 29 
E and I, left). The helix pitch appeared to be constant but difficult to measure (65–120 nm), due 
to a significantly relaxed twist. At the same incubation time, the glycated counterpart formed 
fibrils of similar diameter (16 nm) but with a significantly reduced height (1.6 nm) and length 
(Fig. 29 E and I, right). 
 
At 7-day incubation, both non-glycated and glycated Abeta42 formed the same kind of amyloids 
that they produced at day 3, indicating that the aggregation process was already fully completed. 
The fibres formed by Abeta42 were twisted, 70–125 nm long (5.2-nm height, 14.9-nm diameter) 
and 17.1 nm thick; the ones derived from glycated Abeta42 not only were much shorter (Fig. 29 
F, left and right, respectively) but also less defined in shape, looking more amorphous. These 
results demonstrated that, in the case of Abete42, the structural impact of glycation on the 
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morphology of the aggregates was much greater, influencing both shape and size of the 
aggregates.  
 
Overall, the glycated variants showed thinner and shorter fibres compared to the non-glycated 
ones at the same time point for both Abeta40 and Abeta42. These results thus demonstrated that 
glycation heavily affected the aggregation process both by slowing it down and partially also by 
changing the morphology of the fibres.  
 
 
Figure 24. AFM micrographs of Abeta40 and Abeta42 aggregates in the presence and the absence of 
MGO. The images show that the glycation interferes with the aggregation process either by limiting the 
growth of the fibres or possibly slowing down the aggregation kinetics. A, B and C. Abeta40 and glycated 
Abeta40 images acquired with a magnification of 5, 2 and 1 µm at day 1, 3 and 7 respectively. D, E. F. 
Abeta42NG and glycated Abeta42 images acquired with a magnification of 1 and 5 µm at day 1, 3 and 7. 
G and H Abeta40 and glycated Abeta40 images acquired with a magnification of 3 µm at day 3, 
respectively. Helix pitch is indicated in red. I and L. Abeta42 and glycated Abeta42 images acquired with 
a magnification of 3 µm at day 3, respectively. M. Schematic representation of height, length and diameter 
on a helical structure.   
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Table 4. Measurements of Abeta40 and glycated Abeta40 fibres obtained by AFM. Height and diameter 
are shown at different incubation time (1, 3 and 7 days). 
 Abeta40 Glycated Abeta40 
Incubation time Height Diameter Height Diameter 
1 day 5.4 – 8.2 nm 8.0 – 12.0 nm 4.9 nm N.d. 
3 days 5.1 – 9.6 nm 8.5 – 15.7 nm 6.2 - 8.5 nm 8-16 nm 
7 days 4.0 – 6.0 nm 10.0 - 15.0 nm 6.7 - 9.2 nm 11.8-13.2 nm 
 
Table 5. Measurements of Abeta40 and glycated Abeta40 fibres obtained by AFM. Height and diameter 
are shown at different incubation time (1, 3 and 7 days). 
 Abeta42 Glycated Abeta42 
Incubation time Height Diameter Height Diameter 
1 day 14.2 nm N.d. 4.9 nm 15.0 nm 
3 day 5.3 - 8.7 nm 9-15 nm 1.6 nm 16.0 nm 
7 day 5.2 nm 14.9 nm 17.1nm -N.d. 
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6. Results – IAPP 
At this point of my project, I studied the role of glycation, a pathological process highly relevant 
in diabetes patients, on the structure, aggregation pathway and toxicity of IAPP. Originally, I had 
planned to produce the IAPP peptide using a heterologous protein expression system in 
Escherichia coli (E. coli). I attempted protein expression and purification experiments with both 
rat and human IAPP orthologue forms. I initially tested the expression and purification of the rat 
orthologue since this was described in the literature as much less aggregation prone than the 
human one.  
 
6.1 IAPP purification 
Both rat and human IAPP were initially expressed as a fusion protein in the form leader-IAPP-
intein-CBD (sequence in appendix 2), where CBD stays for chitin-binding domain (Fig. 30). The 
N-terminal leader sequence [MKIEEG(NAP)3E] contained codons that are highly expressed in 
E.coli (MKIEGG) and a bulky, hydrophobic group (NANP repeats) that were used to increase 
solubility and expression of the peptide. The intein and the chitin-binding domain (CBD) acted as 
affinity tags and generated C-terminal amidation. When a CBD-tagged protein is loaded into the 
chitin column, it is captured by the resin and separated from other impurities. The addition of a 
buffer containing ammonium (intein cleavage buffer) cleaves the tag and releases the pure protein.  
 
Cottingham et al. demonstrated that ammonium bicarbonate in the intein cleavage buffer played 
the nucleophilic role by attacking the carbonilic group at the C-terminal (Fig. 30 E) (111). 
Ammonium bicarbonate is the key compound resulting in amide substitution at the cleavage point. 
The remarkable relevance of this method is obtaining the purified protein with the C-terminal 
amidation, which is necessary for protein function (109). The presence of an amide group instead 
of a free acid at the end of the C-terminus can induce significant differences in protein properties, 
including the mechanism of aggregation, cytotoxicity and the morphology of amyloid fibrils 
(108). 
 




Figure 25. Scheme for expression and purification of IAPP. A. The IAPP construct was expressed in E. 
coli cells and loaded onto a chitin column. B. C-terminally amidated IAPP with attached N-terminal leader 
sequence was washed from the column after intein cleavage. C. Wild-type IAPP was generated after 
disulphide oxidation and V8 protease cleavage. D. Nitrogen-sulfur acyl-shift. E. Ammonium addition 
leading to ammonium mediated cleavage. F. C-terminal amidation reaction. 
 
After intein cleavage, leader-IAPP-NH2 was purified by gel-filtration chromatography, which 
separates the desired product from a mixture according to the size and removes excess of salt and 
DTT from the buffer. The removal of DTT is important to allow for the formation of the naturally 
occurring disulphide bond between the two cysteine residues of IAPP. The N-terminal leader 
sequence was removed using V8 protease. V8 protease typically cleaves polypeptide chains 
downstream glutamate residues (184). The only glutamate residue present in our construct of 
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IAPP is located in the last position of the leader sequence. Therefore, cleavage with V8 protease 
releases the leader sequence yielding native IAPP. This protocol was a valuable aspect of this 
method as enable to preserve the C-terminus amidation and also the disulphide bridge between 
Cys2 and Cys7, two features results of two post-translational modifications, both necessary for 
full biological activity (110).  
 
6.1.1 rIAPP purification  
Intein self-splicing was successful, leading to cleavage of ~70% of the fusion construct (SDS-
PAGE Fig. 31 A). The protein obtained (leader-rIAPP-NH2) was analysed by size-exclusion 
chromatography using a Superdex 75 column (120 mL bed volume) to assess whether it was 
monodispersed in solution. Leader-rIAPP-NH2 eluted at 83 mL according to the chromatogram 
reported in Fig. 31 B. This elution volume was consistent with the expected molecular weight 
(5.9 kDa) of leader-rIAPP according to a calibration performed using protein standards. The 
separation was followed by measuring the absorbance at 280 nm and the fractions corresponding 
to rIAPP were combined and concentrated. Protein concentration was estimated using the 
Bradford assay. The final product of leader-rIAPP was highly pure, as assessed by SDS-PAGE. 
However, the purified protein appeared barely visible on SDS-PAGE suggesting very low yields. 
For this reason, the purity of the peptide was checked by silver staining (Fig. 31 A). 
 
 
Figure 26. rIAPP purification. A. Peak fractions of gel-filtration (from 64 to 84 mL) were analysed by SDS-
PAGE and silver staining. rIAPP bands are circled in red. B. rIAPP (HiLoad 16/60 Superdex 75); rIAPP eluted 
a single peak at 83 mL.  
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6.1.2 hIAPP purification 
The human orthologue of IAPP was purified using a protocol similar to the one employed for 
rIAPP (intein cleavage followed by size-exclusion chromatography to obtain the construct leader-
hIAPP-NH2). The gel filtration was performed using a Superdex 75 column (120 ml bed volume). 
Leader-hIAPP-NH2 eluted at 88 mL (Fig. 32 B). This elution volume is consistent with the 
expected molecular weight (5.9 kDa) of leader-hIAPP according to a calibration performed using 
protein standards. The purity of fractions selected from the gel filtration profile was verified by 
SDS-PAGE and silver staining (Fig. 32 A). Pure leader-hIAPP was found in fractions eluted at 
volumes comprised between 86 and 90 mL. 
The yield obtained from both rat and human was very low, and the samples were not suitable for 
my analysis. For this reason, made strong by the experience gained with Abeta, I ordered the 
synthetic full-length IAPP peptide (1-37) from two different companies: Peptide2.0 and 
Eurogentec. The peptides arrived lyophilised and were stored at -20°C until use. All the peptides 
contained physiological modifications, such as the C-terminal amidation and the 2-7 disulfide 
bridge as determined by mass spectrometry and reverse-phase HPLC. The peptide coming from 
Peptide 2.0 Inc was obtained with 98.43% declared purity while that from Eurogentec with 95% 
declared purity.  
 
Figure 27. hIAPP purification. A. Peak fractions of gel-filtration (from 86 to 90 mL) were analysed by 
SDS-PAGE. hIAPP bands are circled in red. B. hIAPP (HiLoad 16/60 Superdex 75). hIAPP eluted at 88 
ml.  
 
         
 92 
6.2 Spectroscopic analysis of MGO 
This project was time-wise initiated after completing the one on the Abeta peptides. In the 
literature, MGO is extensively used in enzymatic studies, and in most all the cases is obtained by 
steam distillation (185) of a commercial 40% solution in water. The low effective concentrations 
of MGO in water and the addition of acid compounds should prevent MGO polymerisation (169). 
When I started my project, I used commercial MGO, purchased from Sigma (cat. n M0252). I 
assumed that the compound would be pure and stable. I understood with time that this was not the 
case. I realised that MGO undergoes complex modifications with time especially if not in the 
presence of suitable quantities of reducing agent. 
 
Since the MGO concentration as compared to the reducing agent and the peptide were very high, 
I realised that the glycating agent could undergo polymerisation and oxidation in aqueous 
conditions as previously described by Nemet et al (186). They showed how solvent, temperature, 
and the amount of available water strongly affected the equilibrium of the different forms of MGO 
and, therefore, it could radically alter its reactivity. In addition, the effective MGO content in 
solutions stored for even short time at the suggested storage temperature (4 °C) is questionable at 
best (169). For these reasons, I concluded that the commercial solution may not be an optimal 
product to carry out the glycation analysis. 
 
To perform experiments on IAPP, I firstly attempted to carry out distillation of MGO thanks to 
the help of collaborators in University College of London. After some attempts to distil MGO, 
the procedure was unfortunately unproductive due to practical reasons. Secondly, another simple, 
convenient, and reproducible method to obtain pure MGO was adopted. The synthesis of high 
purity MGO was carried out from methylglyoxal 1,1-dimethyl acetal (hereafter named acetal) in 
acid conditions at high temperature in phosphate buffer following an the protocol described in 
material and methods (Scheme 2) (169). The acid hydrolysis method is more time consuming, 
but better reproducible and allows an increased and optimal purity compared to the commercial 
MGO. The obtained yield was virtually near 100% as established by 1H NMR (Fig. 33). 
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Scheme 2. Acid hydrolysis of acetal resulting in one molecule of MGO and two of methanol.  
 
 
Scheme 3. Behaviour of MGO in acqueous condition. MGO undergoes a spontaneous reaction with 
water and less than 1% of the MGO has been demostrated to remain unreacted  in aqueous solution 
(141). Two compounds are predominantly formed: methylglyoxal monohydrate and methylglyoxal 




Figure 28. 700 MHz 1H NMR spectra of the reagent acetal and the product MGO with assignment and 
their chemical structure. A. Time zero of the reaction, δ: 2.18 (s, 3H, CH3), 3.4 (s, 3H, CH3), 4.44 (s, 1H 
CH). B. Reaction completed, δ: 2.38 (s, 3H, CH3), 5.4 (s,1H, CH), 4.82 (s,1H, CH).  
Several resonances in the 1H spectrum can be tentatively assigned by comparison with their 
predicted chemical shifts. Acetal, the reagent of the reaction (Scifinder CAS registry n 6342-56-
9), is characterised by the presence of three main hydrogen types (Fig. 33 A): three hydrogens 
belonging to the methyl group in alpha to the carbonyl group, labelled as A in the figure,  in the 
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region of 2.18 ppm; a single hydrogen in alpha to the two oxygens, labelled as B, in the region of 
4.44 ppm; two groups of hydrogens part of the methoxyl groups, labelled as C, in the region of 
3.4 ppm. A potential impurity was detected at around 1.45 ppm. 
At the end of the acid hydrolysis, the reaction product was analysed by means of 1H NMR (Fig. 
33 B). The reaction produced two molecules of methanol per one of MGO, as expected (Scheme 
1). The resulting spectrum showed three signals attributable to MGO at 2.38 ppm, at 4.82 ppm 
and at 5.40 ppm. The first chemical shift was assigned to three hydrogens belonging to the methyl 
group, present both in the acetal and MGO and labelled as A (Fig. 33). The other two signals 
belong to the single hydrogen less shielded, called B in figure 33. 
The presence of two signals for the single hydrogen B is due to a mixture of two MGO forms. 
MGO undergoes a spontaneous reaction with water and it has been estimated that MGO 
predominantly forms two compounds: mono- and dihydrate MGO (Scheme 2) (186-188). Since 
around 99% MGO reacts with water, the only hydrogen belonging to the unreacted aldehyde 
(Scheme 3, left) cannot be detected (141). 
The signal of methanol was assigned as the resonance at 3.4 ppm as reported in predicted chemical 
shifts (Scifinder CAS registry n 67-56-1). The impurity found in the acetal (1.45 ppm) was not 
reactive. I could then conclude that the reaction was successfully completed from the three signals 
attributable to MGO exactly where predicted i.e. at 2.38 ppm, at 4.82 ppm and at 5.40 ppm. The 
satisfying outcome was also testified by the absence of any acetal associated signal. As a result, 
the in-house-synthesised MGO was employed for further glycation experiments on IAPP.  
 
6.3 IAPP sample preparation  
To study properly the peptide aggregation process, it was crucial to dissolve any possible pre-
existing aggregates to detect the reaction starting from the monomeric form.  
IAPP from Peptide2.0 (named IAPP1) was initially treated with HFIP, a strong acid alcohol, as 
often reported in the literature (189-191). After HFIP removal, the peptide, in the form of a thin 
film, was dissolved in buffer and analysed with CD to investigate the secondary structure. The 
treated peptide showed a clear alpha-helix conformation (Fig. 34), maybe caused by the 
interactions of the peptide with traces of the HFIP hydroxyl groups. Surprisingly, the protein 
produced by Eurogentec (named IAPP2) after the same treatment with HFIP showed a 
conformation intermediate between random coil and alpha-helix (Fig. 34). The contrasting 
behaviour of IAPP1 and IAPP2 may derive from a different history determined by different 
production and/or purification methods.  
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I therefore judged the HFIP treatment as not successful, since neither samples were suitable for 
aggregation studies. At this stage, I decided to employ TFA, the strong acid I had previously used 
for the preparation of Abeta peptides in combination with HFIP. I therefore dissolved IAPP1 in 
TFA only, before removing it and preparing the solution in buffer. Under these conditions, IAPP1 
finally showed an reproducible random coil conformation, reasonable starting point to study the 
aggregation process (Fig. 34). From now on, IAPP1, the peptide produced by Peptide 2.0, was 
the only one employed for all experiments and will be from now on referred simply as IAPP. TFA 
(1 ml/mg peptide) was left for one hour at room temperature before being completely removed by 
freeze drying. The peptide film, firmly stack on the vial walls, was dissolved in the appropriate 
buffer by slowly and repeatedly pipetting. The reproducibility of the assay was hard to be obtained 




Figure 29. CD Spectra of IAPP from different sources. IAPP1 from Peptide2.0 pre-treated with HFIP 
(blue line) showed alpha helix conformation, but when treated with TFA (grey line) displayed a random 
coil conformation. IAPP2 produced by Eurogentec after treatment with HFIP was a mixture of random 
coil and alpha-helix conformation. Data are expressed in ellipticity. The spectra were recorded 
immediately after acid pre-treatment. Data are plotted as mean residue molar ellipticity. 
 
6.4 IAPP aggregation studies 
As reported for Abeta peptides, ThT-binding assay was employed to follow the aggregation 
kinetics of IAPP, in the absence or in the presence of increasing concentrations of MGO. The 
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TFA-dried peptide appeared as a thin film on the walls of the tube. The immediate addition of 
buffer to this tube may not guarantee its complete resuspension. Part of the protein could stay 
attached to the walls and the estimation of the protein concentration could be not reliable. To 
ensure full peptide resuspension I decided to add dimethyl sulfoxide (DMSO) to the peptide layer 
to obtain a 1 mM stock solution. DMSO is an organic aprotic solvent which could harvest 
successfully the protein stuck on the tube walls because of its hydrophobic features. In addition, 
it could help dissociate pre-formed aggregates and promoting its monomeric state. Total DMSO 
v/v used never exceeded 2%. The protein stock in DMSO was diluted into PBS to reach the desired 
concentrations and incubated at 37°C.  
 
To identify the ideal peptide concentration which would give me an easy-to-follow aggregation 
kinetics curve, different concentrations ranging from 5 μM to 50 μM were screened. Optimal 
conditions were found using 10 µM IAPP. At this peptide concentration the aggregation curve 
was highly reproducible, the fluorescence was high enough to define a smooth curve but not as 
intense as to saturate the signal, and the kinetics was sufficiently slow to allow for a well-defined 
lag phase. The aggregation kinetics of IAPP by itself and in the presence of increasing molar 
excesses of MGO were studied. Peptide:MGO ratios included 1:0, 1:5, 1:10, 1:20, and 1:100 (Fig. 
35 B).  
 
At this concentration, IAPP did not aggregate substantially for the first 10 hours of incubation. 
The growth phase was stretched for almost 48 hours and full plateau was reached at 72 hours. The 
addition of any amount of MGO seemed to have reduced the slope of the line described by the 
elongation phase. If the value 1 is assigned to the slope of the curve for protein:MGO=1:0, by 
adding 5-molar ratio excess of MGO the slope reduced its value to 0.58, although the total amount 
of aggregates was reduced of only 10%. Further addition of MGO to gain protein:MGO ratios of 
1:10 and to 1:20 showed a proportional effect on the aggregation kinetics. In both cases, the MGO 
addition did not interfere significantly with the lag phase but substantially with the elongation 
rate, increasing the relaxation of the slope and confirming a concentration-dependent effect. With 
protein:MGO ratios 1:10 and 1:20 the slope was reduced to 0.38 and 0.26 and the amount of total 
aggregates to 70% and 50%, respectively. Finally, the addition of 100-fold molar exces MGO 
altered dramatically the aggregation process by decreasing the slope of the aggregation curve to 
a value of 0.32. Under these conditions, despite the plateau was reached after around 48 hours, 
almost one day earlier than the non-glycated IAPP, the maximum fluorescence intensity was 
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around 70% lower than the non-glycated sample. This may be due to the excess of MGO acting 
as co-solvent. 
 
To ensure that the kinetics and the quantitative effect of glycation on IAPP aggregation were 
solely due to MGO and not to DMSO, I defined the IAPP aggregation curve also in the absence 
of the latter.  
 
The TFA pre-treated peptide film was diluted in PBS to reach a concentration of 60 µM and 
incubated at 37°C. The concentration was chosen taking into account all possible losses of protein 
stuck on the tube walls and also to reproduce the conditions used for other assays described below. 
The peptide solution was pipetted carefully to capture the maximum amount of protein from the 
tube walls. The kinetics of aggregation was described by a steep sigmoid, with a lag phase of two 
hours. Between five and six hours the ThT-associated fluorescence emission was at its 90%, 
reaching the full plateau after around 10 hours (Fig. 35 A).  
Under these experimental conditions the aggregation of IAPP seemed faster but it was 
proportionate to the peptide concentration. The shape of the curve described remained the same 
as before. 
 
Collectively, these results indicated that glycation of IAPP by MGO decreases the rate of 
fibrillisation in a molar ratio-dependent manner. MGO did not affect the kinetics of formation of 
a critical nucleus but generally decreases the rate of elongation. In addition, by increasing the 
amount of MGO added to the protein, the final amount of amyloid-like fibres decreases 
proportionally.   
 
By comparing the experiments in the presence and in the absence of DMSO it was possible to 
confirm that glycation affected the aggregation process. By observing the data obtained with 
DMSO treatment, the effect of MGO on IAPP aggregation is remarkable and the decrease in rate 
is easily measurable in a molar ratio-dependent manner. On the other hand, it is valuable to follow 
the proteins’ behaviour in the absence of DMSO, which is the same condition adopted in 
techniques such as NMR and CD. 
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Figure 30. Kinetics of aggregation measured by the variation of the fluorescence signal of ThT. A. 
IAPP:MGO with 0-fold, 5-fold, 10-fold, 20-fold and 100-fold molar excesses of MGO to IAPP, using 10 
µM IAPP concentration from a DMSO stock. Data represented as ThT fluorescence intensity at 485nm 
and expressed as percentages B. The same experiment shown with 60 µM IAPP concentration and also 
excess of MGO. DMSO was not employed. 
 
Table 6. Values of the slopes of each ThT curve. Values obtained fitting elongation phase data. The peptide ratio 
1:0 was assumed as 100%. The ratio has the function to clarify the text. 
IAPP : MGO Slope Percentage % Ratio 
1:0 0.6779 100.0 1 
1:5 0.3914 57.7 0.58 
1:10 0.2573 37.9 0.38 
1:20 0.1786 26.3 0.26 
1:100 0.2154 31.7 0.32 
 
6.5 Effect of glycation on secondary structure of IAPP 
The effect of glycation on the secondary structure of the peptide was monitored by CD 
spectroscopy. Following optimisation experiments, 60 µM IAPP was diluted in phosphate buffer 
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(15mM sodium phosphate, 20mM NaCl), pH 7.4 at 37°C with or without a 20-fold molar excess 
of MGO. 
 
Straight after dissolving IAPP in buffer in the presence and in the absence of MGO, conspicuous 
precipitation was visible in the cuvette. IAPP at time zero presented/indicated a strong band at ca. 
<200 nm, characteristic of a high content of random coil structure. A negative shoulder was also 
distinguishable around 220 nm, suggesting that a mixture of secondary structure characteristics 
may be present (Fig. 36 A). In the two following hours IAPP changed slightly the shape of the 
described curve. After six-hour incubation at 37°C the signature random coil minimum partially 
lost its intensity and slightly moved towards higher wavelength (205 nm), suggesting an increment 
in peptide folding. Instead, the minimum at ca. 220 nm became more pronounced, indicating an 
enrichment of alpha helix and beta-sheet content. CD spectra collected at several time points 
showed that fibril formation is accompanied by a conformational transition towards beta sheet-
rich structures.  
 
In the presence of MGO, the peptide at time 0 displayed the exact same secondary structure as 
non-glycated IAPP. With prolonged incubation at 37°C, the glycation reaction seemed to hinder 
the accumulation of beta-rich structures detectable by this technique (Fig. 36 B). The overall 
signal intensity decreased with time, probably due the precipitation of aggregated peptide.   
After incubation at 37°C, the difference in spectra between non-glycated IAPP and glycating 
IAPP suggested that glycation by MGO interfered with the transition of the secondary structure 
towards beta sheet. The different degree of precipitation may also suggest a difference in the 
morphology of the formed aggregates. 
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Figure 31. CD spectra of IAPP at 60 µM concentration, in the presence and in the absence of MGO 
collected at incubation times at 37°C. Time zero is displayed in red, two-hour incubation in yellow, six-
hour incubation in green, eight-hour incubation in blue and 10-hour incubation in brown. DMSO was not 
employed. A. In the absence of MGO, the alpha- to beta- transition of IAPP during the fibrillation process 
is displayed. B. With a 20-fold molar excess of MGO, IAPP native random coil/alpha helix conformation 
is preserved over time. Data expressed in ellipticity. 
 
6.6 Evaluation of the effect of glycation on IAPP folding  
To sustain the thesis derived from the CD analysis, I employed also NMR, which is a method that 
can provide high-resolution information regarding the chemical shifts of amino acids at different 
time points. This technique may not be ideal for aggregating proteins and for my experimental 
conditions, but it could nevertheless be useful to interpret the results so far obtained. 
I started by tentatively reproducing the 2D TOSCY spectrum found in literature for IAPP. The 
spectrum was therefore acquired at 10 °C, 10 mM sodium phosphate buffer at pH 5.5 (192). The 
lower pH should help to maintain the peptide stability and thus decrease the rate of aggregation, 
also increasing the chances of obtaining a clean spectrum. 2D NMR spectra obtained under these 
conditions revealed a reasonable dispersion of the chemical shifts, as shown in the fingerprint 
region of IAPP (Fig. 37 A, blue). Residue assignments were tentatively carried out and the 
spectrum was qualitatively recognisable with almost half of the 37 amino acids being assigned. 
The two residues more significant as possible glycation sites (Lys1, Arg11) did not appear in the 
spectrum. Moving towards conditions closer to what it has been used so far for the other 
experiments (37 °C at pH 5.5 and 37 °C at pH 7.4), the effect on the number of recognisable peaks 
was dramatic (Fig. 37 B, green). As well known, small unstructured peptides often have no 
detectable spectrum at neutral pH, which was also the case in this experiment. For this reason, I 
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decided to screen 1D 1H NMR spectra at 37°C and both pH 7.4 and 5.5, using always 60 µM 
IAPP in sodium phosphate. I decided to carry out the investigation also at a lower pH since this 
condition is physiologically relevant: IAPP is stored in the acidic environment of secretory 
granules of the beta cells (pH 5.5). 
 
Figure 37. 2D TOCSY spectra of IAPP at 60 µM. A. IAPP at pH 5.5, 10 °C. The fingerprint of the peptide 
corresponds to literature (192). The position of Arg11 should appear as indicated. B. IAPP at pH 5.5, 37 
°C. Temperature has a strong decreasing effect on the shifts and intensity of the spectrum. C. IAPP at pH 
7.4, 37 °C. The additive effect of temperature and pH have a dramatic effect on the spectrum, making it 
very undetectable.  
The effect of the pH at 37 °C was also studied obtaining 1D 1H NMR spectra. (Fig. 38). The 
spectrum registered at pH 5.5 confirmed that IAPP was stable and soluble in this condition. This 
is supported by the fact that IAPP is stored in the acidic (pH 5.5) medium of the secretory granules 
in the beta-cells, where the protein does not aggregate. In stark contrast, at pH 7.4 IAPP resulted 
more aggregated and less folded, according to the 1D 1H NMR spectrum (Fig. 38). This outcome 
is in line with the physiological behaviour of IAPP, which is prone to aggregate when released 
from the vesicles into the blood flow at pH 7.4 (193). Since it is likely that glycation occurs in the 
extracellular space in a neutral pH, I decided to carry on working at a pH 7.4 to investigate the 
effect of MGO on IAPP folding. Further 1D 1H NMR studies were carried out in the presence and 
in the absence of MGO incubated at 37 °C. Spectra were acquired at time zero, after six and 24-
hour incubation but the spectra were not suitable for comparison.  
 
In conclusion, Lys1, Arg11, the two residues more likely to be glycation sites, did not appear in 
the 2D TOCSY spectra obtained at physiological conditions (37 °C, pH 7.4). In both NMR 
experiments 2D TOCSY and 1D 1H, the neutral pH and the higher temperature dramatically 
increased the increase of aggregation preventing the possibility to investigate the effect of 
glycation in physiological conditions. Therefore, the obtained NMR data were inconclusive to 
describe any clear effect of glycation on IAPP folding. 
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Figure 38. Zoom in the aromatic region (9-6 ppm) of 1D 1H NMR spectra of IAPP at pH 5.5 (red) and at 
pH 7.4 (blue). 
 
 
6.7 Identification of IAPP peptides glycation site by mass spectrometry  
Protein glycation products can be described by mass spectrometry analysis (194). MGO-glycation 
reaction could mainly occur on specific functional groups: on the amine functions of lysine 
residues or of the N-terminal, or on the arginine guanidine group, or on the histidine imidazole 
side chain. However, adducts obtained with these two reactive sites were different, and should be 
distinguished on the basis of the observed mass increment. Indeed, modification involving a lysine 
mainly generated carboxyethyl-lysine (CEL, mass increment 72 Da) and carboxymethyl-lysine 
(CML, mass increment 58 Da), whereas if the reaction involves an arginine residue the reaction 
products were hydroimidazolone (mass increment 54 Da) and argpyrimidine (mass increment 80 
Da) (48,49,195). In this work, the formation of two modified species was shown, after 48-hour 
incubation at 37 °C of IAPP with a 10-fold molar excess of MGO. Mass spectrometry analysis of 
these species revealed molecular weights of 3978,2 (quadruply charged ion at m/z 994,4756 Fig. 
39 C) and 3964,2 (quadruply charged ion at m/z 990,9697 Fig. 39 B), respectively corresponding 
to a mass increment of 72,032 Da and 58,009 Da in respect of unmodified peptide,  (theoretical 
weight 3906,3, quadruply charged ion at m/z  976.4675 Fig. 39 A), thus indicating that glycation 
reaction involved an amide function. IAPP structure is characterised by only two reactive amine 
groups: the protein N-terminal and the ε-amine group of Lys1. Since the two groups are located 
on the same amino acid, it was not possible to define which of the two was the actual modification 
site by mass spectrometry, even performing a MS/MS experiment. However, it was demonstrated 
that glycation occurred on the free amino acid group belonging to Lys1 or to N-terminus, leading 
to the formation of CEL and CML. 
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Figure 39. ESI-MS spectrum of IAPP species resulting from the 48-hour incubation of the peptide with a 
10-fold molar excess of MGO at 37 °C. Three compounds were detected: unmodified IAPP (species A) 
whose [M+4H]4+ ion was detected at m/z 976.4675 , IAPP carrying one CML (species B, [M+4H]4+ at 
990,9697) and IAPP carrying one CEL (specie C, [M+4H]4+ at 994,4756). 
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Table 7. IAPP products obtained from MS analysis after incubation in the presence and in the absence of 
MGO. 
Ion (m/z) Peptide Theoretical MW 
977.2163 IAPP (A) 3906.32 
991.7197 IAPP [CML] (B) 3960 
995.2256 IAPP [CEL] (C) 3978 
 
6.8 Analysis of the aggregate morphology of IAPP 
The previous experiments suggested that glycation interfered with aggregation pathway of IAPP 
in a molar ratio-dependent manner. The high-resolution technique AFM was used to obtain a 
three-dimensional image of the morphology of the species formed at different time points for 
IAPP with and without MGO. To obtain representative results, the assay was replicated three 
times. 
 
IAPP and glycated IAPP at a concentration of 10 µM were analysed after three-day incubation at 
37°C. The micrographs of IAPP showed a mostly homogenous population of pre-fibrillar 
oligomers (Fig. 40, top, far left). This species, probably constituted by oligomers at different 
growth stages, occupied the majority of the micrograph. In the micrograph, also sparse individual, 
slightly branched fibres occurred. Although the height of the fibres varied (4.5-7.5 nm), their 
diameter was consistently around 16.5nm, indicative of single fibres.  
 
In stark contrast, the glycated IAPP micrographs acquired after three days incubation at 37°C 
showed a dense field of a networks of disk-like species (Fig. 40, top, middle left). The aggregates 
assembled in a heavy structure characterised by a wreath-like shape. The presence of these bulky 
aggregates could explain the reduction of the CD signal as the consequence of a prominent 
precipitation. Their height was constant (5 nm) and their appearance of flat, interconnected ring-
like structures. Compared to IAPP, the glycated sample clearly showed a different network of 
aggregates and intermediates.  
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To allow the fibres and other species to fully develop, samples were studied also after 17 days of 
incubation 37°C. For IAPP, the longer incubation time increased the density of fibres compared 
to day 3 (Fig. 40, top, right middle). These aggregates appeared needle-like in appearance. They 
were less branched than the previous sample but also showed more self-association. The diameter 
was largely unchanged from day 3 incubation, but the height decreases to 4.5 nm, perhaps 
indicating fibril remodelling. The corresponding glycated sample showed an evolution from disk-
like towards highly-interconnected fibrillar species. The shape of this species was similar to the 
one formed by IAPP after 3-day incubation (Fig. 40, top, far right), although the glycated versions 
were visibly more branching, and disorder compared. The height of these newly-formed fibres 
was ranging between 2 nm and 7 nm, a much broader population than the one found after 3-day 
incubation. This evolution possibly suggested that the disk-like structures may have been indeed 
precursors of the fibrils. 
 
This behaviour supports the evidence that glycation could induce IAPP to adopt a different 
aggregation pathway, also interfering with the kinetics of its fibrillisation. Indeed, the final fibrils 
formed by glycated and non-glycated IAPP showed a similar morphology, despite the very 
different pathway. 
 
Figure 40. AFM micrographs of IAPP aggregates in the presence and the absence of excess MGO. The 
left and right panels correspond to 3-day and 17-day incubation, respectively. IAPP images are displayed 
with a 1 µm scale (top row) and with 0.5 µm scale (bottom row). The images show that glycation interfered 
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with the aggregation process either by changing the morphology of the fibres or possibly slowing down 
the aggregation kinetics. 
 
Table 8. Measurements of IAPP fibres obtained by AFM. Height and diameter are shown at different 
incubation time (3 and 17 days). 
 IAPP Glycated IAPP 
Incubation time Height Diameter Height Diameter 
3 days 




5 nm 14.0 nm 
17 days 4.3 nm 17.5 nm 5.5- 6.7 nm 19.6 nm 
 




In this project, I investigated the effect of glycation, an enzyme-free addition of sugar to proteins, 
and its relation to protein aggregation using Abeta40 and Abeta42, the two main species observed 
in AD patients and IAPP, a peptide intimately associated with hyperglycaemia and T2D. 
Abeta peptides are the main component of amyloid plaques, the extracellular deposits found in 
the brains of patients affected by AD (196). The role of the Abeta peptides in AD appears 
generally causative but many factors are still area of contention: the exact series of events 
involving Abeta amyloidogenesis, the molecular pathways that control pathological aggregation, 
and the precise toxic species of Abeta remain under investigation.  
The most accepted theory is that the main toxic species are the oligomeric states or soluble 
aggregates rather than the mature fibres (197-199). Previous studies have demonstrated that Abeta 
peptides undergo glycation, a post- translational modification of increasing concern because of its 
association with toxic AGE species (200,201). The formation of AGEs, resulting from the reaction 
between reducing sugars and proteins, can alter the biological function of Abeta (46,202). Another 
considerable element that makes glycation a potential remarkable factor in AD is the observation 
that patients affected by diabetes, a disease directly linked to high sugar levels, have higher chance 
(5-fold more) to develop AD than other individuals (203). For this reason, it is extremely urgent 
to enquire whether and how glycation may interfere with the structure and aggregation properties 
of Abeta. 
Employing a multidisciplinary approach, I demonstrated that glycation reduces the aggregation 
speed of both Abeta variants (Abeta40 and Abeta42) in vitro. Obtaining reproducible and reliable 
results was not straightforward. This was because the two processes under investigation, 
aggregation and glycation, are concomitant and partially competing. Aggregation and glycation 
strongly affect each other: glycation, as a post-translational modification, can influence the rate 
of aggregation process by altering the hydrophilic features of a protein (204). In addition, 
aggregation can hamper glycation by hiding the glycation sites and burying them in the core of 
the protein, rendering them unavailable. These two processes, glycation and aggregation, can 
nevertheless be followed independently by exploiting the different spectrofluorometric properties 
of their products.  
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Mass spectrometry was employed to identify the glycation sites by trypsin digestion (194). The 
combination of trypsin digestion and MS analysis identified Arg5 and Lys11 as glycation sites in 
Abeta peptides. The glycation reaction at Arg5 generated the fluorescent product ArgP, the 
formation of which was followed at a specific wavelength. When excited at 320 nm, ArgP emitted 
a fluorescent signal at 405 nm, while ThT, in the presence of amyloid-like structures, emitted at 
485 nm (179) when excited at 440 nm. To investigate the effect of glycation, the glycating agent 
employed was methylglyoxal (MGO) a dicarbonyl compound produced during glucose 
metabolism. In this project, I showed that glycation of Arg5 was completed on both Abeta40 and 
on Abeta42. In particular, glycation of both Abeta variants occurred in a window of roughly 24 
hours, the exact time by which Abeta40 reached the aggregation plateau. To be noticed is that, 
although Abeta42 was completely aggregated in just 12 hours, the glycation, unexpectedly, 
continued for further 12 hours. This interesting behaviour of Abeta42 could be explained in 
several ways. The first reason could be the fact that the arginine, a polar, charged residue, is still 
exposed to the solvent even after complete aggregation. The second reason could be the presence 
of a monomeric species that does not take part in the aggregation process and that is the substrate 
of the glycation reaction occurring in the final 12 hours of the kinetics.  
As shown by ThT binding assays, the aggregation of both Abeta forms was affected by the 
concomitant glycation reaction that slowed down the process without completely hindering it. 
Although ThT binding assay cannot provide qualitative information, the amyloid-like structures 
formed by glycated samples appeared to be reduced compared to the native peptides. This result 
was confirmed by AFM micrographs displaying an apparent smaller amount of fibres and 
aggregates, characterised by a different morphology between glycated and non-glycated samples. 
During the ThT binding assay, the addition of certain amount of MGO to Abeta40 seemed to 
reduce the slope of the sigmoid, corresponding to the elongation phase of the aggregation reaction. 
The addition of MGO also interfered with the lag phase by slowing down the kinetics. The most 
evident effect was detected in the elongation phase of the aggregation (Fig. 24). In the case of 
Abeta40, the effect on the elongation phase was proportional to the increasing amount of MGO, 
indicating a concentration-dependent effect of MGO on the aggregation of this variant of Abeta. 
This result was not reproducible with Abeta42 in the same conditions used for Abeta40. MGO 
had a substantial effect on Abeta42 lag phase but only slightly altered the elongation phase. The 
most prominent effect was noticed on the final amount of aggregates, which was significantly 
reduced compared to non-glycated samples. 
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In addition, the effect of glycation on the secondary structure of Abeta variants was investigated 
by means of circular dichroism (CD) spectroscopy. In the absence of MGO, I observed that 
Abeta42 transited from mixture of beta-sheet and random coil to pure beta-sheet structures and 
that this conformational change was delayed by the glycation reaction. In Abeta40 the transition 
is not visible, as the peptide remained in a random coil conformation. Also, the non-glycated 
Abeta40 showed a clear transition, starting from a mixture containing random coil conformation 
at time zero and transitioning to a beta-sheet conformation after six hours. In the presence of 
MGO, instead, Abeta40 maintained mostly a random coil conformation. (180). Its longer 
permanence in a random coil conformation during the glycation reaction would explain the effect 
of MGO in delaying the elongation phase during the aggregation assay.  
Studies suggested that MGO-glycation of different proteins leads to the formation and 
stabilisation of small and soluble aggregated species that retain native-like structure (205-207). 
Here, I showed that MGO-glycation of Abeta40 has minimal effects on the secondary structure 
of the peptide i.e. the secondary structure of MGO-glycated Abeta40 did not change relative to 
native Abeta40. Possibly, glycation stabilised the unfolded state of the peptide even after 12 hours 
and with a high excess of MGO to Abeta40. Our data should be put in the frame of previous 
results on Abeta peptides using MGO or similar glycating agents. 
Oliveira et al. supported this hypothesis demonstrating that glycation affected the conformational 
stability of proteins (207). This group studied the effect of MGO on cytochrome C, which is not 
involved in amyloidogenic diseases but was previously employed as a model to study protein 
aggregation (208). They proposed that glycation of aggregation-prone proteins could lead to a 
different aggregation pathway. They suggested that instead of undergoing to a canonical 
amyloidogenic pathway, glycated peptides adopt a native-like aggregation one. In support to this 
theory they demonstrated how this native-like aggregation pathway was thermodynamically and 
kinetically more favoured. 
Another study about the effect of glycation on Abeta was carried out employing a different 
glycating agent: Vitek et al. tested the effect of glucose on Abeta40 and a shorter fragment 
(Abeta1-28) (209). Their results showed an increased aggregation rate in the presence of AGE-
modified proteins. In particular, pre-aggregated amyloid aggregates were added to the two Abeta 
variants as seeds. The discrepancy between their results and the ones presented in this work, 
however, could be explained by differences in methodology. They carried out the aggregation 
assays with a monomeric form of Abeta variants observing the formation of amyloid-like 
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structures after four months. An AGE-modified peptide was added to compare the effect of 
glycation. This glycated peptide was already aggregated and was acting as a seed. Therefore, the 
enhanced aggregation could be explained by the presence of AGE nucleation seeds that are well 
known to be responsible for increased aggregation rates.  
Also the work presented by Nomoto et al. (210) employed glucose as glycating agent. The 
glycation reaction resulting from glucose leads to pentosidine, a fluorescent glycation product 
very different from the one obtained from MGO, clearly highlighting how important the specific 
glycating agent is. 
A different study focused on the combination of computational and experimental approaches, 
using glyoxylic acid and cyanogen bromide as glycating agents. (211). The computational 
analysis on Abeta42 focused on the effects of glycation on the free energy of the peptide. The 
glycated Abeta42 monomer was generated by modifying the lysine residues at positions 16 and 
28 to N-(6)-carboxymethyllysine (CML), one of the possible AGEs. CML is an AGE chemically 
very different from CEL and ArgP products that was observed by MS in our study. Their data are 
thus hard to compare with ours.  
Our data are instead in full agreement with a previous study using synthetic Abeta42. This peptide 
was glycated in vitro with the same glycation agent used in this work and was used to study the 
toxicity of glycated Abeta42 on primary hippocampal neurons (200). It was observed that 
glycation exacerbates neurotoxicity of Abeta with up-regulation of the AGE receptor and 
activation of glycogen synthase kinase-3. I suggest an explanation about that this behaviour by 
considering that, according to my results, the slower process of fibre formation could have the 
effect of stabilising the oligomeric state, generally believed to be the toxic species. If true, this 
hypothesis would urgently solicit the identification of new effective ways to prevent sugar 
accumulation in the blood and reduce the risk of Abeta glycation. It was therefore compelling to 
study the effect of glycation on other diabetes-related peptides, such as amylin and, in the future, 
maybe also alpha-synuclein, since this line of research may unveil further important details about 
the relationship between these two pathologies. 
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6.1 IAPP 
A major accepted cause of type-2-diabetes, T2D, is the aggregation of IAPP, a peptide hormone 
co-produced and co-secreted along with insulin from the endocrine beta-cells of the pancreas 
(105). Misfolded IAPP is the primary constituent of amyloid deposits in the pancreatic islets. 
These toxic amyloid-like structures are very similar to the Abeta peptide deposits, often also 
heavily glycated, observed in the brains of patients affected by AD. IAPP can be a good model to 
investigate the effect of glycation on protein aggregation. 
Increasing evidence suggested that the pre-fibrillar oligomers of IAPP were the primary toxic 
agents rather than the amyloid fibrils as in many other aggregation prone proteins (100,212). 
However, in contrast to other peptides such as insulin, immunoglobulin G, alpha synuclein and 
bovine serum albumin, little is known about the effect of glycation on the structural properties 
and aggregation kinetics of IAPP (179,206,213,214). 
IAPP is an intrinsically disordered protein intimately associated with hyperglycaemia. Using a 
combination of spectroscopic and other biophysical techniques, the current work demonstrated 
that glycation affected the aggregation of IAPP by reducing aggregation rates. This effect was 
associated with an altered secondary structure transition and with a different morphology of the 
IAPP aggregates.  
The glycation reaction is a slow reaction under physiological conditions that requires time to show 
its pathological effects (215). At the early stages of modification, lysine, arginine and histidine 
residues are the main available sites of MGO modification (216). However, IAPP structural 
models proposed in the past were unclear as to whether these amino acids were solvent exposed, 
when the protein was monomeric and in solution. (131,133). The exposure of specific residues 
could drastically interfere with the glycation reaction. In this study, I observed that MGO-
glycation of IAPP resulted in the formation of CML and CEL, two of the most common AGEs 
found in the literature (48,49,195). The modification occurred on the amine function belonging to 
the N-terminal of the protein or the ε-amine group of Lys1. Since the two groups are located on 
the same amino acid, it was not possible to define which of the two was the actual modification 
site by mass spectrometry. On the other hand, no production of hydroimidazolone, argpyrimidine 
on Arg11 or MGO-derived products on His18 was detected. This was the first evidence showing 
that glycation occurs at the first IAPP residue, probably because it was the most accessible to 
MGO-modification.  
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Studies suggested that glycation would affect the structural properties and aggregation kinetics of 
proteins in different ways. For example, glycation would alter the rate of formation of amyloid 
fibrils for different proteins (217,218). Here, I demonstrated that MGO-glycation of IAPP slightly 
interfered with the lag phase but dramatically altered the rate of IAPP aggregation, by decreasing 
the slope of the aggregation curve. The decrease was from a value of 0.70 for non-glycated Abeta 
to a final 0.20 for glycated Abeta, as supported by the ThT-binding assays (Fig. 24). The 
proportional increase in elongation during the kinetics induced by increasing excess of MGO 
suggested that the relative concentration of MGO to IAPP played a crucial role. Therefore, MGO-
glycation affected the kinetics of fibril formation in a concentration-dependent manner.  
This work reported that the glycation reaction preserved IAPP native conformation, by blocking 
the alpha-helix-to-beta-sheet transition characteristic of amyloid fibril formation. This was in 
agreement with the reduction of fibril formation observed in ThT kinetic measurements. It also 
suggested a low tendency to conformational changes in glycated IAPP, responsible for blocking 
the seeding nuclei formation, resulting in a reduced fibril formation. The glycated IAPP CD 
spectra displayed a clear reduction in ellipticity signal intensity over incubation time. It could be 
argued that the reason for this signal reduction in the presence of MGO may be peptide 
precipitation, which would also explain the proportional reduction of ThT signal. This hypothesis 
is plausible but is not supported by AFM evidence. According to AFM micrographs, the amount 
of fibres of glycated IAPP were eventually less abundant than the non-glycated counterpart.  
AFM was employed to investigate the morphology of IAPP in the presence and in the absence of 
MGO. Glycation did not affect remarkably the morphology of IAPP but would lead IAPP towards 
a different aggregation pathway: non-glycated IAPP displayed the formation of fibres over 17-
day incubation following a canonical pathway that goes from the monomeric form to fibrillar 
aggregates. Glycated IAPP showed an evolution from disk-like towards highly-interconnected 
fibrillar species. Uniform disk-shaped particles were reported also by Zhu investigating the in 
vitro assembly of a recombinant amyloidogenic low chain variable domain (219). Their high disk-
shaped aggregates converted into oligomers and protofibrils after five-day incubation at 37 °C. 
These data obtained by Zhu correlated with my results showing that disk-like aggregates would 
adopt a different aggregation pathway eventually leading to the formation of fibrillar aggregates.   
My results showed a great difference in terms of aggregates’ crowdedness between glycated and 
non-glycated samples. Although AFM is not a technique providing accurate quantitative 
information, it was clear that both glycated and non-glycated IAPP showed fibres with a similar 
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morphology after 17-day incubation, but with a strong difference in terms of amount of fibres. 
The glycated sample showed a smaller number of fibrillar species, apparently caused by a slower 
aggregation process. This behaviour supported the evidence that glycation induced IAPP to adopt 
a different aggregation pathway, also interfering with the kinetics of its fibrillisation, by slowing 
it down.  
These data partially fitted into a wide framework of studies on IAPP aggregation. It is undeniable 
that IAPP aggregation is very sensitive to residue change and post-translational modifications. 
Indeed, several studies showed that post translational modifications on specific amino acid side 
chains would significantly accelerate or decelerate IAPP aggregation (220,221). Recently, the 
effect of IAPP deamidation, a spontaneous non-enzymatic post translational modification 
resulting in the conversion of asparagine into a mixture of aspartic acid and isoaspartic acid, was 
investigated by two different groups. Dunkelberger et al. demonstrated that IAPP deamidation 
accelerated IAPP self-assembly, by altering the fibres structure (220). In particular, the amino 
acids responsible of this acceleration were identified as Asn14 and Asn21 but not Asn 22, Asn 
31, and Asn 35 (221). Even a small portion of deamidated IAPP (N14D) could have a crucial role 
by inducing the aggregation of wild-type IAPP.  
Glycation of IAPP was previously investigated using similar glycating agents. One of the first 
studies was carried out by Kapurniotu et al. reporting that glycated IAPP was more 
amyloidogenic. The different outcome could lay on several factors. Firstly, they employed D-
glucose as the glycating agent, which was demonstrated to be up to 50,000 times less reactive 
than MGO (37-39). Secondly, the authors obtained a different AGE: they described the conversion 
of the Arg11 guanidine group to an imidazolone. This can be explained by the use a different 
glycating agent. Thirdly, the procedures followed were extremely different. The glucose-
glycation product (AGE-IAPP) was left in incubation for four days and then added to native IAPP. 
The AGE-IAPP worked as a seed and the addition of native IAPP could strongly interfere with 
the enhanced aggregation process.  
These results could possibly be related to the aggregation behaviour of amyloidogenic proteins 
upon glycation. In fact, both insulin and alpha-synuclein, which are involved in amyloid diseases, 
and also cytochrome C, a protein recently used as a model to study protein aggregation, showed 
less amyloid fibril formation after glycation (205-207).  
Another study focused on the relationship between IAPP and sugars was carried out in 2000. This 
noteworthy study demonstrated that glucose has a strong effect on IAPP gene transcription (222). 
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This means that glucose, by controlling IAPP gene transcription, greatly influences the expression 
and the amounts of IAPP. 
Overall, the effect of glucose and its metabolism products on IAPP in the glycation reaction is a 
currently in the spotlights. In this work I demonstrated that glycation slowed down IAPP 
aggregation and this could have serious consequences on IAPP toxicity. Haataja et al. 
demonstrated that IAPP oligomers were the most toxic form among the IAPP aggregates and 
induced membrane leakage and disruption (223). These oligomers were able to cross the plasma 
membrane and appeared to act similarly to prions (224,225). Since glycation slowed down the 
aggregation process, presumably the oligomeric form was maintained for longer time before 
eventually forming amyloid-like aggregates. This means that the glycated IAPP peptides can be 
more toxic as a consequence of their longer persistence as oligomeric species.  
 
6.2 Abeta and IAPP 
T2D and AD are characterised by insoluble protein aggregates with a fibrillar conformation, IAPP 
in T2D pancreatic islets, and Abeta in AD brain (226). IAPP aggregation is associated with 
pancreatic beta-cell loss, whereas Abeta formation is associated with neuronal cell loss. Beta-cell 
loss leads to diabetes, nerve cell loss to dementia. Therefore, T2D and AD have several features 
in common. Studies of the aetiology of these diseases is crucial to understand the mechanism 
undergoing. One of the trigger processes affecting these diseases is protein aggregation of Abeta 
for AD and IAPP for T2D. Although the aggregation of these amyloidogenic proteins has been 
previously studied in vitro, the possibility of a common triggering molecular mechanism is still 
area of contention. 
 
Post translational modifications are known to affect protein structure and function (54,204). Some 
of these modifications may affect proteins stability and lead to their misfolding and accumulation. 
Reducing sugars play an important role in modifying proteins, forming AGEs. The post-
translational modifications responsible for the non-enzymatic addition of sugars to proteins is 
glycation. Recently, much attention has been devoted to the role played by glycation in affecting 
amyloid aggregation and cellular toxicity. Amyloid deposits are often found rich in glycated 
proteins, suggesting a direct correlation between protein glycation and amyloidosis. Vitek et al. 
reported, for the first time in 1994, that plaque fractions of AD brains contained about three-fold 
more AGE adducts than preparations from healthy, age‐matched controls (209). In the same year, 
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this outcome was corroborated by a different group that identified AGEs as major components of 
amyloid plaques, by means of immunohistochemical studies on post-mortem tissues (227).  
 
In summary, this work focused on the molecular effects induced by MGO-glycation in the 
amyloid aggregation of Abeta and IAPP. Overall, glycation decreased the elongation rate in both 
protein kinetics in a concentration-dependent manner. The slower kinetics were also supported by 
the CD data collected to study the peptide secondary structure demonstrating that glycation 
reduced the speed of conformational transitions towards beta sheets. The effect on Abeta40 was 
more visible than on Abeta42. For Abeta40 the transition from random coil to beta-sheet structure 
was firmly halted whereas for Abeta42 variant the transition from a mixture containing beta sheet 
and random coil to pure beta-sheet conformation was considerably delayed. A similar decelerating 
effect was described for IAPP whose secondary structure transition was from random coil/alpha 
helix to beta sheet conformation. The effects of glycation described in this work were highlighted 
by the difference of morphology of fibres from glycated and non-glycated samples. In AFM 
micrographs of both Abeta and IAPP, the glycated samples displayed a smaller amount of fibrillar 
aggregates as compared to the non-glycated peptides incubated under the same conditions at the 
same time points. The smaller amounts of aggregates detected by AFM was in accordance with 
the other data collected with ThT binding assay and by means of CD spectroscopy.  
 
These data suggested that glycation played a crucial role in the aggregation process of peptides 
involved in AD and T2D and it could be the molecular mechanism linking the diseases. This 
should be put in frame with several works. Among these, Li et al. reported that MGO-glycated 
Abeta peptide exacerbated the neuronal toxicity by the upregulation of the receptor for AGEs 
(RAGE) and subsequent activation of death‐signalling pathways. This was explained by the 
relationship between Abeta and RAGE. Abeta peptide was previously identified as a ligand of 
RAGE, and their interaction triggered the activation of different pathways of death‐signalling 
(228). 
 
Another study supporting the link between AD and T2D was presented by Cao et al. suggesting 
the potential role of dietary sugar in the pathogenesis of AD. An incorrect diet and high blood 
glucose play a crucial role in the epidemic of obesity, a major risk factor for T2D. They suggested 
that controlling the consumption of sugar-sweetened beverages could be an effective way to 
curtail the risk of developing AD. In this study, a transgenic mouse model of AD (APP/PSY) fed 
with 10% sucrose-sweetened water was compared with rodents under normal diet. The mice 
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assuming sugar gained weight, developed hyperinsulinemia, hypercholesterolemia and glucose 
intolerance, typical T2D symptoms. Another surprising effect was the memory impairment and 
the 2-3-fold increase in Abeta amyloid-deposition in the brain (229). The exacerbation of cerebral 
amyloidosis in sucrose-treated mice is the evidence supporting that glycation can be the cause of 
the early AD onset on T2D patients.  
 
The results obtained in this work stated that AD and T2D may share a common mechanistic cause. 
According to these outcomes, the correlation could lay on glycation. These findings highlighting 
a clear association between AD and T2D and may give insights to approach them differently. The 
link between these two diseases could open the way to treat them for which symptoms have been 
so far treated separately. This would make an impact in the healthcare system, and on the 
community.  
 
In conclusion, T2D is one of the most common long-term health conditions, characterised by 
serious complications gradually developing as an intrusive and wearing presence in patients’ 
everyday life. Patients affected by neurodegenerative disorders suffer from a significant physical 
and cognitive loss and require intensive, long‐term healthcare, becoming dependent on family or 
caregivers. These diseases are a burden to their patients’ lives. By moving towards the 
identification of new therapeutic strategy, I aim to contribute in the improvement of the health 
and well‐being of these patients. My hope is that the vast community working on misfolding 
diseases, as well as pharmaceutical companies, may take inspiration from this outcome. 
 
  




ABETA 40 (230) 
 
                                   10                                   20                                    30                                  40  
DAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV V  
 
Number of amino acids: 40 
 
Molecular weight: 4329.86 
 
Theoretical pI: 5.31 
 
Amino acids Number of amino acids Composition percentage 
Ala (A) 3 7.5% 
Arg (R) 1 2.5% 
Asn (N) 1 2.5% 
Asp (D) 3 7.5% 
Cys (C) 0 0.0% 
Gln (Q) 1 2.5% 
Glu (E) 3 7.5% 
Gly (G) 6 15.0% 
His (H) 3 7.5% 
Ile (I) 2 5.0% 
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Leu (L) 2 5.0% 
Lys (K) 2 5.0% 
Met (M) 1 2.5% 
Phe (F) 3 7.5% 
Pro (P) 0 0.0% 
Ser (S) 2 5.0% 
Thr (T) 0 0.0% 
Trp (W) 0 0.0% 
Tyr (Y) 1 2.5% 
Val (V) 6 15.0% 
 
Total number of negatively charged residues (Asp + Glu): 6 
Total number of positively charged residues (Arg + Lys): 3 
 
Atomic composition: 
Carbon      C        194 
Hydrogen    H        295 
Nitrogen    N         53 
Oxygen      O         58 
Sulfur      S          1 
 
Formula: C194 H295 N53 O58 S1 
Total number of atoms: 601 
 
Extinction coefficients: 
This protein does not contain any Trp residues. Experience shows that this could result in more 
than 10% error in the computed extinction coefficient. 
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Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
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ABETA 42 (230) 
 
                                   10                                   20                                    30                                  40  
DAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIA  
 
Number of amino acids: 42 
 
Molecular weight: 4514.10 
 
Theoretical pI: 5.31 
 
Amino acids Number of amino acids Composition percentage 
Ala (A) 4 9.5% 
Arg (R) 1 2.4% 
Asn (N) 1 2.4% 
Asp (D) 3 7.1% 
Cys (C) 0 0.0% 
Gln (Q) 1 2.4% 
Glu (E) 3 7.1% 
Gly (G) 6 14.3% 
His (H) 3 7.1% 
Ile (I) 3 7.1% 
Leu (L) 2 4.8% 
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Lys (K) 2 4.8% 
Met (M) 1 2.4% 
Phe (F) 3 7.1% 
Pro (P) 0 0.0% 
Ser (S) 2 4.8% 
Thr (T) 0 0.0% 
Trp (W) 0 0.0% 
Tyr (Y) 1 2.4% 
Val (V) 6 14.3% 
Total number of negatively charged residues (Asp + Glu): 6 
Total number of positively charged residues (Arg + Lys): 3 
 
Atomic composition: 
Carbon      C        203 
Hydrogen    H        311 
Nitrogen    N         55 
Oxygen      O         60 
Sulfur      S          1 
 
Formula: C203 H311 N55 O60 S1 
Total number of atoms: 630 
 
Extinction coefficients: 
This protein does not contain any Trp residues. Experience shows that this could result in more 
than 10% error in the computed extinction coefficient. 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient     1490 - Abs 0.1% (=1 g/l)   0.330 
   





                                   10                                  20                                 30 
KCNTATCAT QRLANFLVHS SNNFGAILSS TNVGSNTY  
 
Number of amino acids: 37 
 
Molecular weight: 3906.32 
 
Theoretical pI: 8.90 
 
Amino acids Number of amino acids Composition percentage 
Ala (A) 4 10.8% 
Arg (R) 1 2.7% 
Asn (N) 6 16.2% 
Asp (D) 0 0.0% 
Cys (C) 2 5.4% 
Gln (Q) 1 2.7% 
Glu (E) 0 0.0% 
Gly (G) 2 5.4% 
His (H) 1 2.7% 
Ile (I) 1 2.7% 
Leu (L) 3 8.1% 
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Lys (K) 1 2.7% 
Met (M) 0 0.0% 
Phe (F) 2 5.4% 
Pro (P) 0 0.0% 
Ser (S) 5 13.5% 
Thr (T) 5 13.5% 
Trp (W) 0 0.0% 
Tyr (Y) 1 2.7% 
Val (V) 2 5.4% 
Total number of negatively charged residues (Asp + Glu): 0 
Total number of positively charged residues (Arg + Lys): 2 
 
Atomic composition: 
Carbon      C        165 
Hydrogen    H        262 
Nitrogen    N         50 
Oxygen      O         56 
Sulfur      S          2 
 
Formula: C165 H262 N50 O56 S2 
Total number of atoms: 535 
 
Extinction coefficients: 
This protein does not contain any Trp residues. Experience shows that this could result in more 
than 10% error in the computed extinction coefficient. 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient     1615 
Abs 0.1% (=1 g/l)   0.413, assuming all pairs of Cys residues form cystines 
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Ext. coefficient     1490 
Abs 0.1% (=1 g/l)   0.381, assuming all Cys residues are reduced 
 
  




Sequence of fusion protein in the form leader-IAPP-intein-CBD. It was subject of intein 
cleavage resulting in C-amidated leader-IAPP protein. 
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